Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Texas
Clinical trial register · United States · industry-sponsored

Clinical Trials in Texas, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 5290 Florida 4430 Illinois 2481 Georgia 2368 Arizona 2238
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca53 Novartis Pharmaceuticals44 Eli Lilly and Company33 Merck Sharp & Dohme LLC31 GlaxoSmithKline31
State
California5290 Florida4430 Illinois2481 Georgia2368 Arizona2238
All 51 states
Target enrolment
to

Trials with a site in Texas

1965 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Molecular Breast Imaging (MBI)-Guided Biopsy
NCT07114679Breast Cancer Detection, Breast Neoplasm, Molecular Imaging, Biopsy
Smart Breast Corp.
Not applicable
250
Texas
2027-06
Not yet open
A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults
NCT07583641Autoimmune Encephalitis (AE)
argenx
Phase 2
170
Arizona, Texas
2027-04-01
Not yet open
Pivotal U.S. Clinical Validation of AI-COA® for Depression and Anxiety
NCT07279038Depression Disorders, Anxiety Disorders
Deliberate Solutions Inc.
Observational
650
Texas
2027-03-01
Not yet open
NG101m Adjuvant Therapy in Glioblastoma Patients
NCT04373785Glioblastoma Multiforme
DrugsTemodar·Temozolomide
NeuGATE Theranostics
Phase 1/2
52
Texas
2027-01-01
Not yet open
A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
NCT07848295Clear Cell Renal Cell Carcinoma (ccRCC)
DrugsCabozantinib·Opdivo·Nivolumab
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
112
Connecticut, New Jersey, New York, Ohio, Texas, Washington
2026-12-31
Not yet open
A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA
NCT07738822Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
DrugVelinotamig specified on specified days
Cullinan Therapeutics Inc.
Phase 1/2
72
Texas
2026-12
Not yet open
Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression
NCT07809906CD123+ Acute Myeloid Leukemia
Orum Therapeutics USA, Inc.
Phase 1
42
Michigan, Texas
2026-12
Not yet open
A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency Anemia
NCT07687784Iron Deficiency Anemia (IDA)
DrugsFerinject·Ferric Carboxymaltose
AFT Pharmaceuticals, Ltd.
Phase 3
1,366
Florida, Texas
2026-12
Recruiting
SPI-1005 in Adults Receiving Cochlear Implant
NCT06340633Hearing Loss, Cochlear Trauma
DrugEbselen
Sound Pharmaceuticals, Incorporated
Phase 2
40
Iowa, Ohio, Pennsylvania, South Carolina, Texas, Wisconsin
2026-12
Not yet open
Study of Eso-SPONGE for Treating Leaks After Upper Gastrointestinal Surgery
NCT07711093Anastomotic Leaks
Boston Scientific Corporation
Not applicable
74
Texas
2026-12
Not yet open
Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies
NCT07839819Advanced Solid Tumor
DrugsPM54·Doxorubicin·Irinotecan
PharmaMar
Phase 1/2
231
Nebraska, Texas
2026-11-12
Not yet open
A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorectal Cancer Expressing HER2
NCT07796763Advanced Colorectal Cancer Expressing HER2
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
48
Texas
2026-11-01
Not yet open
Natural History to Assess Disease in Patients With MPS IIIC
NCT07712003Sanfilippo Syndrome Type C, Mucopolysaccharidosis (MPS) IIIC
Phoenix Nest
Observational
35
Texas
2026-11-01
Not yet open
IKS04 Regimen in Advanced Solid Tumors That Express CA242
NCT07738939Colorectal Cancer, Gastro Esophageal Junctional Cancer, Gastric Cancer (GC), GEJ Adenocarcinoma
Iksuda Therapeutics Ltd.
Phase 1
120
California, Massachusetts, Tennessee, Texas
2026-11
Not yet open
A Study to Predict Atrial Fibrillation (AF) Burden in Participants With PAF and PsAF Treated With the VARIPULSE™ PFA Catheter
NCT07788989Atrial Fibrillation
Biosense Webster, Inc.
Not applicable
2,300
Texas
2026-10-30
Recruiting
A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection
NCT06801223Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
DrugSulbactam -Durlobactam
Innoviva Specialty Therapeutics
Phase 1
48
California, North Carolina, Texas
2026-10-30
Recruiting
NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease
NCT07683325Fibrostenotic Crohn's Disease
DrugOntunisertib
Agomab Spain S.L.U.
Phase 2
320
Florida, Rhode Island, Texas
2026-10-30
Not yet open
A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced Cancer
NCT07851103Advanced Solid Tumour
DrugEzabenlimab
Boehringer Ingelheim
Phase 1
90
Florida, Georgia, Pennsylvania, Tennessee, Texas
2026-10-26
Not yet open
A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss
NCT07663630Non-small Cell Lung Cancer (NSCLC), Cachexia
DrugPonsegromab
Pfizer
Phase 1
80
Illinois, Texas
2026-10-23
Not yet open
A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
NCT07773727Immunoglobulin A Nephropathy (IgAN)
argenx
Phase 2
120
Florida, Texas, Virginia
2026-10-15
Not yet open
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
NCT07613359Antibody-Mediated Rejection (AMR)
DrugMezagitamab
Takeda
Phase 2
36
California, Florida, Maryland, Missouri, New Jersey, New York, Ohio, Texas
2026-10-15
Not yet open
A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients
NCT07722767AML (Acute Myeloid Leukemia)
DrugsCLN-049·Azacitidine·Venetoclax
Cullinan Therapeutics Inc.
Phase 1
90
California, New York, Texas
2026-10-15
Recruiting
A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis
NCT07801495Moderate to Severe Psoriatic Arthritis
DrugDDY391
Novartis Pharmaceuticals
Phase 2
220
Texas
2026-10-14
Not yet open
Perioperative Photobiomodulation in Facial Plastic Surgery
NCT07846631Postoperative Facial Ecchymosis, Postoperative Facial Edema
Elixir MD Inc
Not applicable
40
Texas
2026-10-12
Not yet open
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
NCT07578649Endometrial Neoplasms, Endometrial Cancer
DrugsPF-08634404·Keytruda·Pembrolizumab
Pfizer
Phase 3
600
Florida, Minnesota, Nevada, Ohio, Oregon, Tennessee, Texas, Virginia
2026-10-09
Not yet open
A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A
NCT07830732Haemophilia A
Novo Nordisk A/S
Phase 3
84
Iowa, Louisiana, Minnesota, Missouri, North Carolina, Oklahoma, Pennsylvania, Texas
2026-10-09
Not yet open
Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA
NCT07780968Esophageal Cancer, GastroEsophageal Cancer, Gastroesophageal-junction Cancer, HER2-positive Gastric Cancer
DrugZanidatamab
Jazz Pharmaceuticals
Observational
300
California, Texas
2026-10-01
Not yet open
A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease
NCT07839936Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
DrugVERVE-102
Verve Therapeutics, Inc.
Phase 2
175
Texas
2026-10
Not yet open
Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults
NCT07531043Ocular Hyperemia
DrugApraclonidine Ophthalmic , Unit Preservative Free
Alcon Research
Phase 3
230
Texas
2026-10
Recruiting
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06752356Chronic Inflammatory Demyelinating Polyneuropathy
Kedrion S.p.A.
Phase 3
161
Connecticut, Florida, New Hampshire, Texas
2026-10
Not yet open
A Phase 1b Study to Assess the Safety and Tolerability of AB126 Neural Exosomes in Patients With Moderate to Severe Acute Ischemic Stroke
NCT07813130Acute Ischemic Stroke
Aruna Bio, Inc.
Phase 1
20
Texas
2026-10
Not yet open
Jigsawdio Multisensory Platform for People With Mild Cognitive Impairment, Alzheimer's Disease, or Related Dementias
NCT07839286Alzheimer Disease, Dementia, Mild Cognitive Impairment
Callahan-Young LLC DBA Jigsawdio
Not applicable
80
North Carolina, Texas
2026-10
Not yet open
A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC
NCT07725796Bladder (Urothelial, Transitional Cell) Cancer, NMIBC, Urothelial Carcinoma Bladder, Urothelial Carcinoma in Situ
UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.
Phase 1
30
Arizona, California, Massachusetts, Nebraska, New York, Pennsylvania, South Carolina, Texas
2026-09-30
Recruiting
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT07336472Multiple Myeloma
DrugIBI3003
Fortvita Biologics (USA)Inc.
Phase 1/2
360
Arizona, California, Georgia, New York, Texas
2026-09-30
Recruiting
A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT07029945Geographic Atrophy
Biojiva LLC
Phase 1/2
152
Arizona, Mississippi, Nevada, Ohio, Texas, Utah, Washington
2026-09-29
Recruiting
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
NCT07705607Diabetic Retinopathy, Macular Edema
DrugsTiespectus·Eylea·Aflibercept
Merck Sharp & Dohme LLC
Phase 3
1,104
Florida, South Carolina, Texas
2026-09-25
Recruiting
Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral Radiculopathy
NCT06956014Lumbosacral Radiculopathy
Vertanical GmbH
Phase 3
810
Texas
2026-09-22
Recruiting
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
NCT07776691Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer
DrugsR-DXd·Mvasi·Avastin·Bevacizumab
Merck Sharp & Dohme LLC
Phase 3
802
District of Columbia, Texas
2026-09-18
Recruiting
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
NCT07701941Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer
DrugsPatritumab deruxtecan·Trastuzumab deruxtecan
Daiichi Sankyo
Phase 1/2
220
California, Colorado, Connecticut, Massachusetts, New York, Oregon, Tennessee, Texas
2026-09-17
Recruiting
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
NCT07412704Arthritis, Rheumatoid
Bristol-Myers Squibb
Phase 1/2
84
California, Colorado, Florida, New York, Oregon, Pennsylvania, Texas
2026-09-15
Not yet open
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
NCT07807345Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer
DrugPembrolizumab
Sutro Biopharma, Inc.
Phase 1
285
California, Florida, Massachusetts, Oklahoma, Texas, Virginia
2026-09-14
Recruiting
Comparison of ACUVUE® OASYS MAX 1-Day Multifocal and DAILIES® AquaComfort Plus® Multifocal
NCT07788521Visual Acuity
Johnson & Johnson Vision Care, Inc.
Not applicable
150
Florida, Georgia, Missouri, New York, Rhode Island, Tennessee, Texas, Virginia
2026-09-10
Recruiting
Evaluation of Approved Contact Lenses (CR-6657)
NCT07819305Visual Acuity
Johnson & Johnson Vision Care, Inc.
Not applicable
150
Florida, Illinois, New York, Ohio, Tennessee, Texas, Virginia
2026-09-10
Recruiting
A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
NCT07416552Metastatic Colorectal Cancer
Hoffmann-La Roche
Phase 1
180
Nebraska, Texas, Wisconsin
2026-09-08
Recruiting
A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide
NCT07793929End Stage Renal Disease, Renal Impairment, Obesity, Overweight
DrugRibupatide
Kailera
Phase 1
32
Florida, Texas
2026-09-08
Not yet open
A Trial of Inebilizumab in Participants With Autoimmune Hepatitis
NCT07598825Autoimmune Hepatitis, AIH
DrugInebilizumab
Amgen
Phase 3
180
Arkansas, California, Indiana, Texas
2026-09-07
Recruiting
A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec
NCT07444450Muscular Atrophy, Spinal
DrugSalanersen
Biogen
Phase 3
42
Texas
2026-09-04
Recruiting
A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
NCT07782957Nasal Polyps
DrugGSK5784283
GlaxoSmithKline
Phase 3
218
Texas
2026-09-03
Recruiting
BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT07755904Cardiomyopathy, Hypertrophic Obstructive
DrugMetoprolol
Braveheart Bio, Inc.
Phase 3
210
New York, South Carolina, Texas
2026-09-02
Recruiting
MBA Early Feasibility Study
NCT07564375Thoracic Aortic Aneurysm, Penetrating Aortic Ulcers (PAUs), Thoracic Aortic Dissection, Pseudoaneurysm
W.L.Gore & Associates
Not applicable
20
California, Ohio, Texas
2026-09-02
Not yet open
A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers
NCT07811232Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
DrugsAL58805·AL8326·Eribulin·Fulvestrant
Advenchen Pharmaceuticals, LLC.
Phase 1/2
138
Texas
2026-09-01
Not yet open
Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD)
NCT07681778Leber Congenital Amaurosis, Leber Congenital Amaurosis (LCA)
Opus Genetics, Inc
Phase 1/2
10
Arizona, Pennsylvania, Texas
2026-09-01
Recruiting
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)
NCT07645248Asthma
GlaxoSmithKline
Phase 3
110
Florida, Kentucky, Missouri, Nevada, Oregon, South Carolina, Texas
2026-09-01
Recruiting
Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis
NCT07588672Seasonal Allergic Rhinitis (SAR), Allergic Rhinitis
Polyrizon Ltd.
Not applicable
120
Illinois, Missouri, New Jersey, Texas
2026-09-01
Recruiting
Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
NCT07654283Hepatitis B, Chronic
DrugAHB-137
AusperBio Therapeutics Inc.
Phase 2
70
California, Maryland, New York, Texas
2026-09-01
Not yet open
A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers
NCT07811297Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
DrugsAL58805·Catequentenib·CCNU·Temozolomide
Advenchen Pharmaceuticals, LLC.
Phase 1/2
138
Texas
2026-09-01
Not yet open
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
NCT07808697SARS-CoV-2
DrugsMRNA-1283·Efluelda (TIV-HD) and Spikevax
ModernaTX, Inc.
Phase 2
300
California, Florida, Illinois, Michigan, Ohio, Texas, Utah, Virginia
2026-09-01
Not yet open
Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections
NCT05750589Retinal Disease
iRenix Medical, Inc.
Phase 3
240
Texas
2026-09-01
Not yet open
Investigation of the Interplay Between Local Oral Inflammation, Microbiota and Systemic Immune Responses.
NCT06966492Gingival Inflammation
Colgate Palmolive
Phase 4
20
Texas
2026-09
Not yet open
Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer
NCT07325214Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Cancer
IMGT Co., Ltd.
Not applicable
360
Massachusetts, Texas, Virginia
2026-09
Not yet open
A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein)
NCT07801300Healthy Volunteers, C-Reactive Protein
Eli Lilly and Company
Phase 1
204
Florida, Texas
2026-09
Not yet open
An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab
NCT07832136Thyroid Eye Disease
Viridian Therapeutics, Inc.
Phase 4
30
California, Florida, Massachusetts, Michigan, Missouri, New Jersey, Texas
2026-09
Recruiting
REC-7735 in Participants With Solid Tumors
NCT07819136Solid Tumors
Recursion Pharmaceuticals Inc.
Phase 1/2
90
Michigan, Texas, Virginia
2026-09
Not yet open
Evaluation of Two Monthly Silicone Hydrogel Multifocal Toric in Soft Contact Lens Wearers
NCT07829419Astigmatism, Myopia
CooperVision International Limited (CVIL)
Not applicable
60
New York, Ohio, Texas
2026-09
Not yet open
A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy
NCT07808073Obesity, Overweight
Eli Lilly and Company
Phase 1
184
Florida, Texas
2026-09
Not yet open
Clinical Outcomes After Treatment of Distal Humerus Fractures With the LORRAINE 2.5/3.5 mm Distal Humerus System
NCT07774091Intra-Articular or Extra-Articular Distal Humerus Fracture, Distal Humerus Fracture
Bonebridge AG
Observational
100
Texas
2026-09
By invitation
Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study
NCT07197788Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Type 2 Diabetes
Endogenex, Inc.
Not applicable
50
Florida, Massachusetts, New Jersey, North Carolina, Texas
2026-09
Not yet open
HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass Surgery
NCT07646210Advanced Heart Failure, Ischemic Heart Failure
HELP Therapeutics Co., Ltd.
Phase 1/2
12
Texas
2026-09
Not yet open
A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight
NCT07808060Obesity, Overweight
DrugsCombined contraceptive·Eloralintide
Eli Lilly and Company
Phase 1
34
Florida, Texas
2026-09
Recruiting
An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)
NCT07426419Dilated Cardiomyopathy (DCM), BAG3 Mutation Associated Dilated Cardiomyopathy
Affinia Therapeutics
Phase 1/2
22
Florida, Missouri, Texas
2026-09
Recruiting
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
NCT07506863Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia
DrugMitapivat
Agios Pharmaceuticals, Inc.
Phase 3
54
Georgia, New York, Pennsylvania, Texas
2026-09
Not yet open
An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults
NCT07578363Ocular Hyperemia
DrugApraclonidine Ophthalmic , Unit Preservative Free
Alcon Research
Phase 3
178
Texas
2026-09
Recruiting
A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)
NCT07748403Wilson Disease, Wilson's Disease, Wilsons Disease
Prime Medicine, Inc.
Phase 1/2
42
Connecticut, Illinois, Texas
2026-09
Recruiting
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
NCT07807163Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2
160
Texas
2026-09
Recruiting
L19IL2/TNF in Patients With Basal Cell Carcinoma
NCT07227870Locally Advanced Basal Cell Carcinoma
DrugDaromun
Philogen S.p.A.
Phase 2
92
Florida, Georgia, New York, Ohio, Texas
2026-09
Recruiting
Hormone-free Antral Retrieval for Viable Embryo Storage & Transfer
NCT07801105Infertility
Kevin Doody
Not applicable
30
Texas
2026-09
Not yet open
Reduction of Anxiety Through Dual Treatment: Digital CBT & NBHWC Coaching
NCT07140497Hearing Disability, Anxiety, Mobility Disability
Toivoa Inc
Not applicable
200
Delaware, New Jersey, Ohio, Texas
2026-09
Recruiting
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
NCT07228442Locally Advanced Cutaneous Squamous Cell Carcinoma
DrugDaromun
Philogen S.p.A.
Phase 2
92
California, Georgia, Massachusetts, North Carolina, Ohio, Texas
2026-09
Recruiting
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia
NCT07517133Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
DrugMitapivat
Agios Pharmaceuticals, Inc.
Phase 3
45
California, Georgia, New York, Pennsylvania, Texas
2026-09
Recruiting
Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC
NCT07722741HCC
DrugsGNOS-PV02·INO-9012
Geneos Therapeutics
Phase 2
90
Georgia, Louisiana, Maryland, Michigan, New York, Texas, Washington
2026-09
Not yet open
SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
NCT07857616Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, Metastatic Solid Cancers, Non Small Cell Lung Cancer
DrugSI-B036
SystImmune Inc.
Phase 1
424
Connecticut, Florida, Oklahoma, Tennessee, Texas
2026-09
Not yet open
Reduction of Depression Through Dual Treatment: Digital CBT & NBHWC Coaching
NCT07195292Hearing Disability, Depression, Mobility Disability
Toivoa Inc
Not applicable
200
Delaware, New Jersey, Ohio, Texas
2026-09
Not yet open
Trial of NASHA Dx Urethral Bulking System
NCT07850804Urinary Incontinence, Urinary Incontinence (UI), Urinary Incontinence , Stress, Urinary Incontinence Due to Urethral Sphincter Incompetence
Palette Life Sciences, Inc.
Not applicable
314
California, Nebraska, North Carolina, Pennsylvania, Texas
2026-09
Not yet open
A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
NCT07766005Hidradenitis Suppurativa (HS)
DrugsSPY072·Bimekizumab
Spyre Therapeutics, Inc.
Phase 2
150
California, Indiana, Kentucky, Louisiana, Massachusetts, New York, South Carolina, Texas
2026-09
Not yet open
Newborn Brain Assessment - CergenX Wave
NCT07857070Neonatal Encephalopathy, Neonatal Encephalopathy (Neonatal Hypoxic-ischemic Encephalopathy), Neonatal Encephalopathy, Unspecified
CergenX Limited
Observational
165
Texas
2026-09
Recruiting
Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism
NCT07805356Hypoparathyroidism, Chronic Hypoparathyroidism
DrugEncaleret
Calcilytix Therapeutics, Inc., a BridgeBio company
Phase 3
160
Nevada, North Carolina, Texas
2026-08-31
Recruiting
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
NCT07569926Prostate Cancer
DrugPiflufolastat
Blue Earth Diagnostics
Phase 4
142
California, Georgia, Massachusetts, Missouri, Oregon, Texas
2026-08-31
Not yet open
Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)
NCT07603557Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia
DrugsZola-cel·Fludarabine Phosphate·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
52
Massachusetts, Texas, Washington
2026-08-31
Recruiting
A Study of COVID-19 Vaccine(s) in Children and Adults
NCT07798648COVID-19 Vaccines
DrugComirnaty
BioNTech SE
Phase 3
700
Florida, Georgia, Hawaii, Kentucky, Ohio, Pennsylvania, Texas, Utah
2026-08-31
Recruiting
A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)
NCT07791043Liver Diseases, Alcoholic
DrugEfimosfermin alfa
GlaxoSmithKline
Phase 2
274
Kansas, Texas
2026-08-31
Not yet open
Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting
NCT07542314Duchenne Muscular Dystrophy
DrugSirolimus
Sarepta Therapeutics, Inc.
Phase 4
20
Texas
2026-08-31
Not yet open
Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
NCT07718737NSCLC (Advanced Non-small Cell Lung Cancer)
DrugsAMT-116·Ramucirumab·Docetaxel
Multitude Therapeutics Inc.
Phase 2/3
512
Florida, Texas
2026-08-28
Recruiting
A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism
NCT07699471Hypoparathyroidism
MBX Biosciences
Phase 3
160
Florida, Louisiana, Nevada, New York, North Carolina, South Carolina, Texas, Washington
2026-08-26
By invitation
Aspire In Vitro Maturation Study
NCT07789730Infertility, In Vitro Maturation of Oocytes, Assisted Reproduction Technologies
Inception Fertility Research Institute, LLC
Not applicable
40
Texas
2026-08-26
Recruiting
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
NCT07493304Venous Thromboembolism (VTE)
DrugsCenvacibart·Apixaban
Regeneron Pharmaceuticals
Phase 3
1,600
Florida, New York, Texas
2026-08-26
Not yet open
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
NCT07735637Newly Diagnosed Multiple Myeloma (NDMM)
DrugsASCT·AZD0120·Melphalan·Lenalidomide
AstraZeneca
Phase 3
750
Florida, Georgia, Illinois, Michigan, Minnesota, Ohio, Texas, Washington
2026-08-25
Active, closed
A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007)
NCT07748351Healthy
Merck Sharp & Dohme LLC
Phase 1
48
California, Texas
2026-08-25
Not yet open
A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma
NCT07772921Asthma
DrugTilrekimig
Pfizer
Phase 3
1,100
Texas
2026-08-24
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
NCT07772492Severe Alopecia Areata
DrugUpadacitinib
AbbVie
Phase 3
300
California, Florida, Idaho, Indiana, Nebraska, Ohio, Texas
2026-08-24
Recruiting
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
NCT07700056Chronic Pruritus of Unknown Origin
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
180
Florida, Georgia, Indiana, New York, Ohio, South Carolina, Texas
2026-08-24
Not yet open
A Phase I Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD4144
NCT07783308Hepatic Impairment
DrugAZD4144
AstraZeneca
Phase 1
30
Arizona, Florida, Texas
2026-08-24
Recruiting
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
NCT07737743Sjögren's Disease
DrugDDY391
Novartis Pharmaceuticals
Phase 2
344
Florida, Illinois, Oklahoma, Pennsylvania, Texas
2026-08-24
Recruiting
A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema
NCT07812090Diabetic Macular Edema (DME)
DrugsBGE-102·Anti-VEGF
BioAge Labs, Inc.
Phase 2
180
Texas
2026-08-21
Not yet open
First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors
NCT07686068Participants With Advanced Solid Tumor Malignancies
VelaVigo Bio Inc
Phase 1/2
260
Texas, Utah, Virginia
2026-08-18
Recruiting
A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation
NCT07625215Atrial Fibrillation
Bayer
Phase 2
360
California, Colorado, Massachusetts, Michigan, North Carolina, Texas
2026-08-18
Recruiting
VEL-101 to Prevent Rejection After Kidney Transplantation
NCT07290777Transplantation, Kidney
DrugTacrolimus
Veloxis Pharmaceuticals
Phase 2
120
Texas
2026-08-18
Recruiting
Pivotal Study of N-acetyl-L-leucine for CACNA1A
NCT07221292CACNA1A, Spinocerebellar Ataxia Type 6, Episodic Ataxia Type 2, Familial Hemiplegic Migraine-1
DrugN-Acetyl-L-Leucine
IntraBio Inc
Phase 3
60
Maryland, Massachusetts, Texas
2026-08-17
Recruiting
A First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of HMB-003 in Healthy Volunteers
NCT07798505Healthy Adult Participants
Hemab ApS
Phase 1
40
Texas
2026-08-17
Recruiting
Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere VT)
NCT07585968Ventricular Tachycardia
Medtronic Cardiac Ablation Solutions
Not applicable
260
Indiana, New York, North Carolina, Ohio, Texas
2026-08-17
Recruiting
A Study of LY4355756 in Healthy Participants
NCT07765498Healthy
DrugMidazolam
Eli Lilly and Company
Phase 1
123
Texas
2026-08-17
Recruiting
Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07733674Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC)
Radiomedix, Inc.
Phase 1
20
Texas
2026-08-15
Not yet open
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
NCT06732245Obesity and Overweight
DrugTirzepatide
Biomed Industries, Inc.
Phase 2
224
California, Florida, New York, Texas
2026-08-15
Recruiting
Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFU
NCT07565506Diabetic Foot Ulcers (DFUs)
Lakewood-Amedex Inc
Phase 2
24
California, Florida, Texas
2026-08-14
Recruiting
Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function
NCT07751250Healthy Participants, Hepatic Impairment
DrugCasdatifan
Arcus Biosciences, Inc.
Phase 1
16
Texas
2026-08-14
Recruiting
A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
NCT07540897Narcolepsy Type 1
DrugAlixorexton
Alkermes, Inc.
Phase 3
150
Florida, Georgia, Michigan, Missouri, North Carolina, Ohio, South Carolina, Texas
2026-08-13
Recruiting
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity
NCT07767175Overweight, Obesity
DrugSemaglutide
Novo Nordisk A/S
Phase 1
142
Kansas, Texas
2026-08-12
Recruiting
A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer
NCT07693751Colorectal Cancer (Locally Advanced or Metastatic)
SOTIO Biotech a.s.
Phase 1/2
100
Texas, Virginia
2026-08-12
Not yet open
A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants
NCT07766369Healthy Volunteers
DrugE2086
Eisai Inc.
Phase 1
93
Texas
2026-08-12
Recruiting
A Study of V132 in Healthy Older Participants (V132-001)
NCT07712575Healthy
DrugsCapvaxive·Prevnar 20
Merck Sharp & Dohme LLC
Phase 1
280
California, Florida, Missouri, Nebraska, Ohio, Rhode Island, Texas
2026-08-12
Recruiting
Study to Assess KN3835 in the Treatment of Flexible/Semi-Flexible Hammertoe (HMT)
NCT07759362Flexible Hammertoe, Semi-flexible Hammertoe
Endo USA Inc., a Keenova Therapeutics Company
Phase 3
554
California, Florida, Texas, Utah
2026-08-11
Recruiting
A Study of LY3971297 in Participants With Heart Failure
NCT07547540Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic
Eli Lilly and Company
Phase 1
90
Michigan, Missouri, North Carolina, Texas
2026-08-11
Recruiting
Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD
NCT07770828Dry Age-related Macular Degeneration
Ocugen
Phase 3
237
Arizona, Pennsylvania, Texas
2026-08-11
Recruiting
Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors
NCT07408258Advanced Solid Tumor
OncoC4, Inc.
Phase 1
20
New York, Pennsylvania, Texas
2026-08-10
Recruiting
A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions
NCT07734064Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
Astellas Institute for Regenerative Medicine
Phase 1
30
Arizona, Ohio, Texas
2026-08-10
Recruiting
A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines
NCT07756580Glabellar Lines
DrugsAGN-151586·Botox
AbbVie
Phase 1
120
Arizona, California, Louisiana, Massachusetts, North Carolina, Tennessee, Texas
2026-08-10
Not yet open
Safety and Efficacy of a 2,910 nm Fractional Ablative Fiber Laser (UltraClear®) for Improvements of Skin Laxity and Lifting of the Lower Face, Submental, and Neck Treatment Areas
NCT07759817Skin Laxity (Submental and Neck), Skin Lifting and Tightening
FA Corporation
Not applicable
50
Kentucky, Texas
2026-08-07
Not yet open
Robotic Minimally Invasive Benign Hysterectomy Post-market Clinical Study With the DEXTER Robotic System
NCT07746531Hysterectomy, Benign Uterine Diseases
Distalmotion SA
Observational
112
Kansas, Texas
2026-08-07
Recruiting
The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
NCT07612878COPD (Chronic Obstructive Pulmonary Disease)
DrugDupilumab
Sanofi
Observational
350
Indiana, North Carolina, Texas
2026-08-06
Recruiting
A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia
NCT07778836Friedreich Ataxia, Friedreich's Ataxia
DrugNomlabofusp
Larimar Therapeutics, Inc.
Phase 3
150
Illinois, New Jersey, Texas
2026-08-05
Recruiting
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis
NCT07720375Non-cystic Fibrosis Bronchiectasis
DrugGalvokimig
UCB Biopharma SRL
Phase 2
300
Florida, Pennsylvania, Texas
2026-08-05
Recruiting
A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV
NCT07698600HIV -1 Infection
BioNTech SE
Phase 1
126
Texas
2026-08-04
Recruiting
An Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the Face
NCT07729579Actinic Keratosis (AK)
Sun Pharmaceutical Industries Limited
Phase 1
48
Texas
2026-08-04
Recruiting
Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille Syndrome After Liver Transplantation
NCT07335523Exocrine Pancreatic Insuficiency
Digestive Care, Inc.
Observational
30
Colorado, New York, Ohio, Oregon, Tennessee, Texas, Washington
2026-08-03
Recruiting
Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease
NCT07227896Parkinson's Disease
AbbVie
Observational
100
Texas
2026-08-03
Recruiting
A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
NCT07734493Schizophrenia
Leal Therapeutics, Inc
Phase 1
90
Arkansas, California, Florida, Georgia, Maryland, New Jersey, Texas
2026-08-03
Recruiting
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
NCT07723248Metastatic Castration Resistant Prostate Cancer
DrugsRinzimetostat·Xtandi·Taxotere·Darolutamide
ORIC Pharmaceuticals
Phase 3
600
Florida, Indiana, Michigan, North Carolina, Ohio, South Carolina, Tennessee, Texas
2026-08-03
Recruiting
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
NCT07516093B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsBexobrutideg·Pirtobrutinib
Nurix Therapeutics, Inc.
Phase 3
620
Georgia, Indiana, Tennessee, Texas, Virginia
2026-08-03
Not yet open
MRI Evaluation of Graft Maturation Following ACL Reconstruction
NCT07046000ACL Tears
Skye Biologics Holdings, LLC
Observational
10
Texas
2026-08-01
Not yet open
Patient Empowerment Project (PEP) Study
NCT07725458Infertility, Mental Health
Inception Fertility Research Institute, LLC
Observational
100
Florida, Texas
2026-08
Recruiting
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
NCT07424833Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation), Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Ascentage Pharma Group Inc.
Phase 1
180
California, Florida, Michigan, New Jersey, Texas
2026-08
Not yet open
Evaluation of Orthokeratology Lenses With a 5MM Optic Zone Diameter
NCT07751172Myopia, Astigmatism
CooperVision International Limited (CVIL)
Not applicable
70
California, Texas
2026-08
Not yet open
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes
NCT07712562Bone Marrow Failure Syndromes, Aplastic Anemias, Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Relapse
DrugDibotatug
Dren Bio
Phase 1/2
60
California, Florida, Georgia, New York, Ohio, Texas, Virginia, Washington
2026-08
Recruiting
A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors
NCT07460375Advanced Solid Tumors
LigaChem Biosciences, Inc.
Phase 1/2
191
Massachusetts, New York, South Carolina, Texas
2026-08
Not yet open
Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains
NCT07436611Port Wine Stains
DrugRapamycin
AFT Pharmaceuticals, Ltd.
Phase 2
30
Texas
2026-08
Recruiting
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
NCT07520006B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsBexobrutideg·Obinutuzumab·Venetoclax·Rituximab
Nurix Therapeutics, Inc.
Phase 1/2
150
Colorado, Florida, Oregon, Pennsylvania, Tennessee, Texas
2026-08
Recruiting
A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants
NCT07727538Familial Chylomicronemia Syndrome
DrugOlezarsen
Ionis Pharmaceuticals, Inc.
Phase 3
12
Alabama, California, Texas
2026-07-31
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
NCT07738614Obesity, Overweight
DrugsEloralintide·Acetaminophen
Eli Lilly and Company
Phase 1
56
Texas
2026-07-31
Recruiting
A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
NCT07722546Graves' Disease
DrugFelzartamab
Biogen
Phase 2
60
Arizona, California, Florida, Maryland, North Carolina, Texas
2026-07-30
Not yet open
Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer
NCT07707674Metastatic Pancreatic Cancer
DrugXNW28012
Evopoint Biosciences Inc.
Phase 1
24
Michigan, New York, Ohio, Oklahoma, Tennessee, Texas
2026-07-30
Recruiting
A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)
NCT07681271Papulopustular Rosacea
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 2
100
Texas
2026-07-30
Recruiting
First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors
NCT07700160Advanced Solid Tumors
VelaVigo Bio Inc
Phase 1/2
230
California, Michigan, New York, Texas, Virginia
2026-07-30
Recruiting
Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD
NCT07435129Facioscapulohumeral Muscular Dystrophy, FSHD
DrugApitegromab
Scholar Rock, Inc.
Phase 2
60
Texas
2026-07-30
Recruiting
Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment
NCT07708727HIV-1-infection
DrugsGS-3242·B/F/TAF·Lenacapavir
Gilead Sciences
Phase 2/3
700
Florida, Georgia, Missouri, Texas
2026-07-29
Recruiting
Prospective Post Market Clinical Registry for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH Spring System Registry
NCT07538622BPH (Benign Prostatic Hyperplasia)
Zenflow, Inc.
Observational
300
Arizona, California, Florida, Idaho, New York, South Carolina, Texas
2026-07-29
Recruiting
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
NCT07749586Advanced Solid Tumor
DrugPembrolizumab
Arvinas Inc.
Phase 1/2
499
North Carolina, Texas, Virginia
2026-07-29
Recruiting
A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations
NCT07514858Parkinson's Disease
DrugLu AF28996
H. Lundbeck A/S
Phase 2
150
Michigan, Texas
2026-07-28
Recruiting
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
NCT07688213Dementia, Alzheimer's Type, Alzheimer's Disease
Sanofi
Phase 2
160
California, Florida, Massachusetts, New Jersey, Oregon, Pennsylvania, Texas
2026-07-28
Recruiting
Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease
NCT07348640Steno-occlusive Disease
DrugsGadopiclenol·Gadoterate meglumine
Guerbet
Phase 3
315
California, Colorado, Illinois, Minnesota, Texas, Washington
2026-07-28
By invitation
Gotistobart Long Term Extension (LTE) Study
NCT07659379Advanced Solid Tumor
DrugGotistobart
OncoC4, Inc.
Phase 3
20
Texas
2026-07-28
Recruiting
A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder
NCT07759128Generalized Anxiety Disorder
DrugUlotaront
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
576
Arizona, Florida, Nevada, New York, Texas
2026-07-28
Recruiting
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
NCT07680946Schizophrenia
DrugUblituximab
TG Therapeutics, Inc.
Phase 2
60
Arkansas, Texas
2026-07-27
Recruiting
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
NCT07570862Lupus Nephritis, Systemic Lupus Erythematosus, SLE - Systemic Lupus Erythematosus, Lupus Nephritis - WHO Class III
DrugFT819
Fate Therapeutics
Phase 2
53
California, Florida, Nebraska, North Carolina, Texas
2026-07-27
Recruiting
Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
NCT07750886Non-Hodgkin Lymphoma, T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma
Natera, Inc.
Observational
200
Texas
2026-07-27
Recruiting
ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain
NCT07568015Greater Trochanteric Pain Syndrome, Greater Trochanteric Pain Syndrome of Both Lower Limbs, Lateral Hip Pain
DrugTriamcinolone acetate
Brixton Biosciences, Inc.
Not applicable
100
Arizona, Georgia, Louisiana, Massachusetts, New Jersey, Oklahoma, Pennsylvania, Texas
2026-07-27
Recruiting
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
NCT07725939Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
DrugGalvokimig
UCB Biopharma SRL
Phase 2
402
Ohio, Pennsylvania, Texas
2026-07-27
Recruiting
Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)
NCT07763197Non-Muscle Invasive Bladder Cancer, NMIBC, High-risk Non-Muscle Invasive Bladder Cancer
Natera, Inc.
Observational
400
Texas
2026-07-27
Recruiting
AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer
NCT07617337ALK Positive Non-small Cell Lung Cancer
DrugLorlatinib
Chugai Pharmaceutical
Phase 1
102
Texas
2026-07-24
By invitation
Case-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils
NCT07639853Arteriovenous Malformation, Gastrointestinal Bleed, Gastric Varices, Hemorrhoid
Medtronic Endovascular
Observational
30
New York, Texas
2026-07-24
Recruiting
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
NCT07755436Ovarian Cancer, Endometrial Cancer, Platinum-resistant Ovarian Cancer (PROC), Metastatic Ovarian Cancer
ArriVent BioPharma, Inc.
Phase 1
180
Florida, Massachusetts, Tennessee, Texas, Virginia
2026-07-23
Recruiting
A Study to Evaluate MAR002 for Acromegaly
NCT07641179Acromegaly
DrugMAR002
Marea Therapeutics
Phase 2
72
Arizona, Ohio, Texas
2026-07-23
Recruiting
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07704892Metabolic Dysfunction-associated Steatohepatitis
DrugEfimosfermin alfa
GlaxoSmithKline
Phase 3
380
Arkansas, California, Florida, Missouri, New York, North Carolina, Ohio, Texas
2026-07-22
Recruiting
Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer Cycle
NCT07453069Vaginal Dysbiosis
DrugFB-301
Freya Biosciences ApS
Phase 2
30
Kansas, Massachusetts, North Carolina, Texas
2026-07-22
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
NCT07659782Non-Small Cell Lung Cancer
DrugVS-7375
Verastem, Inc.
Phase 2
105
California, Florida, Georgia, New Jersey, New York, Texas, Virginia
2026-07-22
Recruiting
A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07701993Metabolic Dysfunction-associated Steatohepatitis
DrugEfimosfermin alfa
GlaxoSmithKline
Phase 3
1,740
Arkansas, California, Florida, Missouri, Texas
2026-07-22
Recruiting
Safety and Efficacy of J147 in Acute Ischemic Stroke
NCT07430917Acute Ischemic Stroke
Abrexa Pharmaceuticals, Inc.
Phase 2
196
California, Illinois, New York, Oregon, Texas
2026-07-22
Recruiting
A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants
NCT07730554Forehead Lines
DrugAGN-151586
AbbVie
Phase 2
80
California, New York, North Carolina, Texas
2026-07-22
Recruiting
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
NCT06987539Generalized Myasthenia Gravis
DrugInebilizumab
Amgen
Phase 2
15
Pennsylvania, Texas, Washington
2026-07-21
Recruiting
DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.
NCT07635563Obstructive Sleep Apnea (OSA)
DrugAcetazolamide
Incannex Healthcare Ltd
Phase 2
120
California, Florida, Louisiana, Maryland, Ohio, South Carolina, Tennessee, Texas
2026-07-21
Recruiting
A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3
NCT07807241Advanced and/or Metastatic Solid Tumors Known to Express B7-H3
Myricx Pharma Limited
Phase 1
120
Florida, Texas, Virginia
2026-07-20
Active, closed
A Study of Eloralintide (LY3841136) in Healthy Participants
NCT07701083Healthy Volunteers
DrugEloralintide
Eli Lilly and Company
Phase 1
58
Florida, Texas
2026-07-20
Not yet open
Evaluation of SofWave Sofware-Guided Energy Delivery for Lower Face and Neck Rejuvenation
NCT07723664Facial Wrinkles, Jawline Contour, Skin Laxity
Sofwave Medical LTD
Not applicable
30
Texas
2026-07-20
Recruiting
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
NCT07594106Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
DrugsREGN4336·Cemiplimab
Regeneron Pharmaceuticals
Phase 1/2
265
Arizona, California, Florida, Illinois, Missouri, Texas
2026-07-20
Recruiting
A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283
NCT07712393Asthma
DrugGSK5784283
GlaxoSmithKline
Phase 1
24
Texas
2026-07-17
Recruiting
DBC-664 in Adult Patients With Solid Tumors
NCT07705035Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
Duboce Biopharmaceuticals, Inc.
Phase 1
210
Colorado, Michigan, New Jersey, New York, Tennessee, Texas
2026-07-17
Recruiting
A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors
NCT07703878Solid Tumor
Gilead Sciences
Phase 1
302
Michigan, Texas
2026-07-17
Recruiting
A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma
NCT07532265Severe Asthma
Kinaset Therapeutics Inc
Phase 2
512
California, Florida, Illinois, Missouri, North Carolina, Pennsylvania, South Carolina, Texas
2026-07-16
Not yet open
MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
NCT06549751Pancreas Cancer, Pancreatic Cancer Metastatic, Pancreatic Cancer (Unresectable)
Marker Therapeutics, Inc.
Phase 1
38
Texas
2026-07-16
Recruiting
Dozee Validation for Contactless Heart Rate and Respiration Monitoring in Clinical Settings
NCT07735403No Specific Medical Conditions or Disease States
Turtle Shell Technologies Pvt. Ltd.
Observational
20
Texas
2026-07-15
Recruiting
A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
NCT07643155Hepatic Impairment
DrugTreprostinil Palmitil
Insmed Incorporated
Phase 1
30
California, Florida, Texas
2026-07-14
Recruiting
A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome
NCT07503444Rett Syndrome
DrugFintepla
UCB BIOSCIENCES, Inc.
Phase 3
200
Arkansas, Florida, Georgia, Pennsylvania, Texas, Washington
2026-07-14
Recruiting
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
NCT07682961HIV Infections
DrugsTeropavimab·Zinlirvimab·Rilpivirine·Cabotegravir
Gilead Sciences
Phase 3
590
California, Florida, Georgia, Michigan, Missouri, Texas, Virginia, Washington
2026-07-14
Recruiting
HB-adMSCs for the Treatment of Crohn's Disease
NCT07077746Crohn Disease (CD)
Hope Biosciences Research Foundation
Phase 2
46
Texas
2026-07-14
Recruiting
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis
NCT07660835Moderate-to-Severe Atopic Dermatitis
DrugNemolizumab
Galderma R&D
Phase 2
35
Texas
2026-07-13
Recruiting
REal-world Clinical evAulation of Medtronic NeurOVascular Products for Acute Ischemic Stroke (RECANOVA Registry)
NCT07599904Acute Ischemic Stroke
Medtronic Neurovascular Clinical Affairs
Observational
1,500
Michigan, New York, Texas
2026-07-13
Not yet open
Pilot Usability Study to Set Up and Use the Feetsee™ Foot Monitoring Device in Adults With Diabetes
NCT07666087Diabetes
Diabetis JSC
Observational
20
Texas
2026-07-10
Recruiting
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
NCT07673627AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG), MG - Myasthenia Gravis, gMG
DrugEmpasiprubart
argenx
Phase 2
40
Florida, New York, Tennessee, Texas
2026-07-10
Recruiting
Evaluate Advanced Pneumatic Compression Device With Revised Compression Programming for Lymphedema Treatment
NCT07613931Lower Extremity Lymphedema
DrugsIC-Green·Indocyanine Green
Tactile Medical
Phase EARLY_PHASE1
5
Texas
2026-07-09
Recruiting
Comparative Self-collection for Cervical Cancer Screening Pivotal Study
NCT07758140HPV, HPV - Anogenital Human Papilloma Virus Infection
Mel Mont Medical
Not applicable
260
Arizona, California, Florida, Idaho, Montana, North Carolina, Texas, Washington
2026-07-09
Recruiting
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
NCT07516951Idiopathic Pulmonary Fibrosis
Chiesi Farmaceutici S.p.A.
Phase 2
240
Missouri, Texas
2026-07-08
Recruiting
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
NCT07602842Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
InduPro, Inc.
Phase 1/2
132
California, Florida, Indiana, New York, Texas
2026-07-08
Recruiting
Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation
NCT07575269Paroxysmal Atrial Fibrillation (PAF), Persistent Atrial Fibrillation
Boston Scientific Corporation
Not applicable
571
Arkansas, Georgia, Iowa, New York, Ohio, Pennsylvania, South Carolina, Texas
2026-07-07
Recruiting
A Study in Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus to Test the Effects of NDI-5001 Given for Multiple Days and to Test How NDI-5001 is Tolerated and Taken up in the Body
NCT07525960Diabetes Insipidus
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 1
24
Florida, Texas
2026-07-07
Recruiting
A Post-Market Assessment of the Safety and Performance of the TriClip™ System
NCT07586995Tricuspid Regurgitation (TR)
Abbott Medical Devices
Observational
1,000
California, Illinois, Texas
2026-07-02
Recruiting
Axonics R20 Post-Market Clinical Follow-up (PMCF) Study for the Indication of Fecal Incontinence
NCT07499258Fecal Incontinence
Axonics, Inc.
Observational
55
New York, Tennessee, Texas
2026-07-02
Recruiting
Phase 1b/2 Study of IV Sarilumab in Adult With RA
NCT07704580Rheumatoid Arthritis
DrugSarilumab
Sanofi
Phase 1/2
140
Florida, Pennsylvania, Texas
2026-07-02
Recruiting
LINQ® Procedure vs. Conventional Medical Management for Sacroiliac Dysfunction
NCT07558278Sacroiliac Joint Pain
PainTEQ, LLC
Phase 4
200
Texas
2026-07-01
Active, closed
A Study of Food Effect on Tersolisib (LY4064809) in Healthy Participants
NCT07662798Healthy
DrugTersolisib
Eli Lilly and Company
Phase 1
60
Kansas, Texas
2026-07-01
Recruiting
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07719361Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms
Flare Therapeutics Inc.
Phase 1
60
California, Massachusetts, Michigan, New Jersey, South Carolina, Tennessee, Texas
2026-07-01
Not yet open
A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)
NCT07650357Advanced Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Carcinoma, Colorectal Cancer
Clasp Therapeutics, Inc.
Phase 1
140
North Carolina, Pennsylvania, Tennessee, Texas
2026-07
Recruiting
A Multi-Site Study to Assess the Effect of Availability of a Heated Tobacco Product on Smoking Abstinence Among Current Primary Cigarette Smokers
NCT07710820Smoking, Tobacco
RAI Services Company
Not applicable
1,060
Florida, Illinois, Nevada, Texas
2026-07
Recruiting
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
NCT07593092Ovarian Cancer
DrugXmAb541
Xencor, Inc.
Phase 1
90
New York, Texas
2026-06-30
Recruiting
EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
NCT07523581Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive
Eloxx Pharmaceuticals, Inc.
Phase 2
24
California, Colorado, Minnesota, New Jersey, Pennsylvania, Texas
2026-06-30
Not yet open
Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)
NCT07161843Acute Renal Failure (ARF), Acute Tubular Necrosis
DrugEseronate
Ebima Clifford Okundaye
Phase 2/3
500
Texas
2026-06-30
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
NCT07581002Acute Myeloid Leukemia
DrugsPivekimab Sunirine·Azacitidine·Venetoclax
AbbVie
Phase 2/3
660
California, Florida, Georgia, Missouri, New York, Texas
2026-06-30
Not yet open
FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade Glioma
NCT07609472High-Grade Glioma (WHO III-IV)
FluoGuide A/S
Phase 2
76
Florida, New Hampshire, Pennsylvania, Texas, Utah
2026-06-30
Recruiting
A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07643766Atopic Dermatitis
DrugENV-294
Enveda Therapeutics
Phase 2
200
California, Florida, Indiana, Texas
2026-06-29
Recruiting
ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer
NCT07452224Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugPembrolizumab
iLeukon Therapeutics, Inc.
Phase 2
80
California, Texas
2026-06-29
Recruiting
A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant
NCT07508787Renal Transplant Failure and Rejection
DrugsSiplizumab·Rabbit anti-thymocyte globulin·Thymoglobulin
Nefro Avillion Clinical Development, LLC
Phase 2
120
California, Florida, Georgia, Michigan, New Jersey, Texas, Washington
2026-06-29
Recruiting
Study of NTB-928 in R/R OC
NCT07690189Relapsed/Refractory Ovarian Carcinoma
TeneoSeven, Inc.
Phase 1
90
Alabama, Nebraska, New York, Texas
2026-06-29
Recruiting
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
NCT07647510Myasthenia Gravis, Generalized
DrugClaseprubart
Dianthus Therapeutics
Phase 3
195
California, Florida, North Carolina, Texas
2026-06-29
Recruiting
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
NCT07284602Idiopathic Pulmonary Fibrosis (IPF)
DrugsDeupirfenidone·Pirfenidone
PureTech
Phase 3
1,100
California, Massachusetts, Nevada, Pennsylvania, South Carolina, Tennessee, Texas
2026-06-26
Recruiting
Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis
NCT07565103Bacterial Conjunctivitis
Senju USA, Inc.
Phase 1/2
426
Texas
2026-06-25
Recruiting
A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
NCT07654972Obesity, Overweight
Eli Lilly and Company
Phase 1
108
Texas, Utah
2026-06-24
Recruiting
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
NCT07705334Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer
SHY Therapeutics
Phase 1
30
Arizona, Colorado, Texas
2026-06-24
Recruiting
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
NCT07488923Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic NEC (GEP NEC), Neuroendocrine Prostate Cancer (NEPC)
Moonlight Bio, Inc
Phase 1
110
Missouri, New Jersey, New York, Tennessee, Texas
2026-06-23
Recruiting
Post-Approval Study of PALMAZ MULLINS XD™ in Treating Pulmonary Artery Stenosis
NCT07122518Pulmonary Artery Stenosis
Cordis US Corp.
Observational
35
California, Georgia, Michigan, Missouri, Nebraska, Ohio, Pennsylvania, Texas
2026-06-23
Not yet open
HALO Clarity™ Cranial Alternating Current Stimulation Therapy for Adults With Moderate-to-Severe Insomnia
NCT07659366Moderate to Severe Insomnia
Nexalin Technology
Not applicable
160
Texas
2026-06-22
Recruiting
A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer
NCT07505771Solid Malignancies
Immunome, Inc.
Phase 1
105
Alabama, California, Texas
2026-06-19
Recruiting
Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)
NCT07600749Malignant Neoplasm
Merck Sharp & Dohme LLC
Phase 1
120
Texas
2026-06-18
Recruiting
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
NCT07564401Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Novartis Pharmaceuticals
Phase 1/2
80
Kentucky, Texas, Washington
2026-06-16
Recruiting
A Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA)
NCT07606274LMNA-Related Dilated Cardiomyopathy
Nuevocor Pte. Ltd.
Phase 1/2
21
Alabama, California, Massachusetts, Michigan, Minnesota, Ohio, Texas
2026-06-16
Recruiting
Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers
NCT07632001Diabetic Foot Ulcers (DFUs), Diabetic Foot, Chronic Wounds
Reprise Biomedical, Inc.
Not applicable
180
Arizona, Florida, Massachusetts, Missouri, New York, Ohio, Oklahoma, Texas
2026-06-15
Recruiting
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
NCT07647328ER-Positive HER2-Negative Breast Cancer
DrugsCamizestrant·Ribociclib
AstraZeneca
Phase 3
150
California, Georgia, Illinois, Kentucky, Nevada, South Dakota, Tennessee, Texas
2026-06-15
Not yet open
A Post Market Trial Assessing the Accuracy of Normal Mode Reading vs. ProScan Reading With the NaviCam SB System. This is a Comparison of Retrospectively Obtained Capsule Endoscopy Videos With a New AI Reading Tool; no New Interventions Will be Completed.
NCT07633847Small Bowel Bleeding
AnX Robotica Corp.
Observational
92
New York, Texas
2026-06-15
Recruiting
Efficacy and Safety of Novosis Putty in Transforaminal Lumbar Interbody Fusion for Patients With Lumbar Degenerative Disc Disease
NCT07017634Degenerative Disc Disease
CGBio Inc.
Phase 3
316
Arkansas, California, Florida, Louisiana, Ohio, Pennsylvania, Texas, West Virginia
2026-06-11
Recruiting
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
NCT07570316Graves' Disease, Graves Disease
DrugEfgartigimod PH20
argenx
Phase 3
230
California, Florida, Kansas, Michigan, Missouri, New York, Texas
2026-06-10
Recruiting
Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections
NCT07220915Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
DrugPanzyga
Octapharma
Phase 3
360
Arizona, Texas
2026-06-10
Recruiting
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation
NCT07626281Inclisiran Formulation
DrugInclisiran
Novartis Pharmaceuticals
Phase 1
152
Kansas, Texas, Utah
2026-06-09
By invitation
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
California, Florida, Louisiana, Rhode Island, Texas, Washington
2026-06-08
Recruiting
An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
NCT07593391Phelan-McDermid Syndrome
DrugNNZ-2591
Neuren Pharmaceuticals Limited
Phase 3
180
Alabama, California, Maryland, Massachusetts, New York, Ohio, Texas
2026-06-08
Recruiting
Water Vapor Ablation for Prostate Cancer: Long-Term Registry
NCT07455058Prostate Cancer
Francis Medical Inc.
Observational
2,500
Louisiana, Minnesota, Texas, Virginia
2026-06-05
Recruiting
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
NCT07359820FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Elevar Therapeutics
Phase 2
30
Arizona, Florida, Illinois, Massachusetts, Minnesota, New York, Texas
2026-06-04
Recruiting
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
NCT07629960Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
Blueprint Medicines Corporation
Phase 1/2
265
Florida, Louisiana, Massachusetts, Michigan, New Jersey, New York, Tennessee, Texas
2026-06-04
Recruiting
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
NCT07645820Atopic Dermatitis
Castle Biosciences Incorporated
Observational
450
Arizona, Maryland, Michigan, Missouri, Nevada, New Hampshire, Texas, Virginia
2026-06-04
Recruiting
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
NCT07590934Metastatic Prostate Cancer
DrugsAZD2287·FPI-2265·Palacaparib·Docetaxel
AstraZeneca
Phase 1/2
152
California, Florida, Louisiana, Minnesota, Nebraska, New York, Oregon, Texas
2026-06-03
Recruiting
Study of ALK-001 on the Progression of Stargardt Disease
NCT07419334Stargardt Disease
DrugALK-001
Alkeus Pharmaceuticals, Inc.
Phase 3
230
Arizona, Colorado, Florida, Massachusetts, Michigan, Ohio, Pennsylvania, Texas
2026-06-03
Recruiting
An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis
NCT07620392Rheumatoid Arthritis
DrugAfimkibart
Hoffmann-La Roche
Phase 2
120
Florida, Louisiana, Texas
2026-06-03
Recruiting
Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region
NCT07566286Chin Augmentation
Galderma R&D
Not applicable
100
Connecticut, Florida, Georgia, Maryland, Tennessee, Texas
2026-06-03
Recruiting
A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
NCT07646587COPD (Chronic Obstructive Pulmonary Disease)
DrugWIN378
Windward Bio
Phase 2
105
California, Florida, Massachusetts, North Carolina, Oregon, Pennsylvania, Texas
2026-06-02
Recruiting
Study of GS-2426 in Participants With Advanced Solid Tumors
NCT07601243Advanced Solid Tumors
Gilead Sciences
Phase 1
174
Michigan, New Jersey, New York, Texas
2026-06-02
Recruiting
Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration
NCT07630649Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Adverum Biotechnologies, Inc.
Phase 2
15
Arizona, California, Florida, Hawaii, Illinois, New Jersey, South Carolina, Texas
2026-06-02
Recruiting
A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension
NCT07661329Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH)
YS Life Science Co., Ltd.
Phase 3
600
California, Florida, Georgia, Kentucky, Missouri, Texas
2026-06-02
Recruiting
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
NCT07586618Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia ALL
Allterum Therapeutics, Inc
Phase 1
24
Colorado, Indiana, New York, Ohio, Pennsylvania, Texas
2026-06-01
Recruiting
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
NCT07227350Locally Advanced Basal Cell Carcinoma
DrugsDaromun·L19IL2·Onfekafusp alfa
Philogen S.p.A.
Phase 2
180
Florida, Georgia, North Carolina, Ohio, Texas
2026-06-01
Recruiting
Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis
NCT07290140Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Airiver Medical, Inc.
Not applicable
300
Alabama, California, Colorado, Iowa, Kentucky, Pennsylvania, South Carolina, Texas
2026-06-01
Recruiting
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
NCT07484022Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
DrugsEnfortumab Vedotin·Pembrolizumab
Generate Biomedicines
Phase 1
37
California, Florida, Georgia, Illinois, New Jersey, New York, Texas, Virginia
2026-06
Not yet open
A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
NCT06287918Solid Tumors With FGFR2 Alterations, Adult
Drug3HP-2827
3H (Suzhou) Pharmaceuticals Co., Ltd.
Phase 1
130
Arizona, Texas
2026-06
Recruiting
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
NCT07524322Breast Cancer, Ovarian Cancer, Endometrial Cancer, PIK3CA Mutation
Regor Pharmaceuticals Inc.
Phase 1
63
California, Texas, Virginia
2026-06
Not yet open
Contact Lens Trial Fitting Experience
NCT07600645Presbyopia
CooperVision International Limited (CVIL)
Not applicable
25
Texas
2026-05-31
Recruiting
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
NCT07480356Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
DrugTARA-002
Protara Therapeutics
Phase 3
284
Arizona, Arkansas, California, Georgia, Missouri, South Carolina, Texas
2026-05-29
Recruiting
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
NCT07607587Obesity, Overweight
DrugCagrilintide
Novo Nordisk A/S
Phase 1
114
California, Florida, North Carolina, South Carolina, Tennessee, Texas
2026-05-29
Recruiting
A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.
NCT07456046KRAS P.G12D
D3 Bio (Wuxi) Co., Ltd
Phase 1
42
Connecticut, Texas
2026-05-29
Recruiting
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
NCT07607964Systemic Lupus Erythematosus, Rheumatoid Arthritis
AbbVie
Phase 1
30
Alabama, California, Florida, Illinois, Tennessee, Texas
2026-05-28
Recruiting
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
NCT07604571Advanced HR+/HER2- Breast Cancer
DrugsLetrozole·Fulvestrant
Novartis Pharmaceuticals
Phase 1
194
Connecticut, Texas
2026-05-28
Recruiting
Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
NCT07623668Optic Neuritis
DrugMethylprednisolone
Oculis
Phase 3
210
Michigan, South Carolina, Texas
2026-05-28
Recruiting
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
NCT06915233Chondral Defect, Articular Cartilage Defect
Vericel Corporation
Phase 3
309
California, District of Columbia, Kansas, North Carolina, Texas, Virginia
2026-05-28
Recruiting
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
NCT07559474Hepatic Insufficiency, Liver Diseases
DrugINCB123667
Incyte Corporation
Phase 1
16
Arizona, Florida, Texas
2026-05-27
Recruiting
Phase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma
NCT07665892Safety in Asthma Patients
Aspeya, Inc.
Phase 1
40
Arizona, California, Texas
2026-05-26
Recruiting
A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure
NCT07615010Pneumonia
MiNK Therapeutics
Phase 2
90
California, Texas
2026-05-26
Recruiting
Clareon TruPlus Study
NCT07502456Aphakia, Astigmatism
Alcon Research
Not applicable
122
Arizona, Ohio, South Carolina, Texas, Utah
2026-05-26
Recruiting
Intratumoral N17350 in Advanced Solid Tumors
NCT07339176Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin, Melanoma
Onchilles Pharma Inc
Phase 1/2
275
California, New York, Texas
2026-05-25
Recruiting
Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
NCT07599982Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
DreaMed Diabetes
Not applicable
102
Maryland, Michigan, New York, North Carolina, Texas, Utah
2026-05-25
Recruiting
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
NCT07570979Metastatic Castration-resistant Prostate Cancer (mCRPC)
DrugsAbiraterone·Enzalutamide
Novartis Pharmaceuticals
Phase 1
208
Massachusetts, Texas
2026-05-25
Recruiting
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT07477587Multiple Myeloma (MM)
Shanghai Henlius Biotech
Phase 1
258
Arkansas, Florida, Indiana, Louisiana, Texas, Washington
2026-05-25
Recruiting
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
NCT07527910Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
DrugsAln-Pnp·Tirzepatide
Regeneron Pharmaceuticals
Phase 2
204
Arizona, California, Florida, Louisiana, Texas
2026-05-22
Recruiting
Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency
NCT07636590Limbal Stem Cell Deficiency
Claris Biotherapeutics, Inc.
Observational
500
Indiana, Kansas, Kentucky, Minnesota, Oregon, Tennessee, Texas
2026-05-22
Recruiting
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
NCT07527923Healthy Volunteer, Atopic Dermatitis
Regeneron Pharmaceuticals
Phase 1
144
Alabama, California, South Carolina, Texas
2026-05-22
Recruiting
Trial of Ureteroscopy vs Steerable Continuous Flow Aspiration Technology
NCT07101809Urolithiasis, Stones, Kidney, Renal Stones, Kidney Stones
Calyxo, Inc.
Not applicable
150
Alabama, Florida, New York, Pennsylvania, Texas
2026-05-21
Recruiting
Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies
NCT07644039Advanced Malignancies
DrugsPM54·Pembrolizumab
PharmaMar
Phase 1/2
119
New York, Texas, Virginia
2026-05-21
Recruiting
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
NCT07578571Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer
Immunome, Inc.
Phase 1
175
Connecticut, Florida, Massachusetts, Texas
2026-05-21
Recruiting
Phase 1/2 Study of UI-102 in Selected Advanced Cancers
NCT07605962Advanced Cancer
United Immunity, co., Ltd.
Phase 1/2
140
Texas
2026-05-20
Recruiting
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT07306832Acute Myeloid Leukemia
DrugPivekimab Sunirine
AbbVie
Phase 1
18
California, Georgia, New York, Tennessee, Texas
2026-05-20
Not yet open
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07400107Obesity, Overweight, Diabetes Mellitus, Type 2
DrugsNNC0487-0111·Semaglutide
Novo Nordisk A/S
Phase 3
1,000
Florida, Georgia, Idaho, Maryland, Michigan, Texas, Virginia
2026-05-20
Recruiting
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
NCT07541287IgA Nephropathy
DrugJADE101
Jade Biosciences, Inc.
Phase 2
30
California, Colorado, Florida, Texas
2026-05-19
Active, closed
A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)
NCT07222189Colitis Ulcerative, Crohn's Disease
DrugBalinatunfib
Sanofi
Phase 2
325
Texas
2026-05-19
Recruiting
A Study of JNJ-1761981 in Participants With Solid Tumors
NCT07525141Neoplasms
DrugCetrelimab
Johnson & Johnson Enterprise Innovation Inc.
Phase 1
66
Florida, Minnesota, New York, Texas
2026-05-18
Recruiting
A Study of TAK-755 in Adults With Acute Ischemic Stroke
NCT07392450Acute Ischemic Stroke
DrugTAK-755
Takeda
Phase 2
222
Arizona, California, Massachusetts, New York, Pennsylvania, Tennessee, Texas
2026-05-17
Recruiting
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
NCT07599670Alzheimer's Disease
AbbVie
Phase 1/2
210
California, Colorado, Florida, Massachusetts, Tennessee, Texas
2026-05-15
Recruiting
IS-001 Injection in Patients Undergoing Robotic-Assisted Colorectal Surgery
NCT07346066Ureter Injury
Intuitive Surgical
Phase 3
146
California, Connecticut, Florida, Nevada, Ohio, Texas, Washington
2026-05-14
Recruiting
A Study to Determine the Effects of ENDS Flavor Availability on Abstinence Within Smokers
NCT07598136Smoking, Tobacco
RAI Services Company
Not applicable
1,280
Florida, Georgia, Missouri, North Carolina, Pennsylvania, Texas
2026-05-14
Recruiting
iDose TR Administration in an Office-Based Surgery Setting
NCT07816692Open Angle Glaucoma (OAG), Ocular Hypertension (OHT)
Glaukos Corporation
Observational
30
Texas
2026-05-13
Recruiting
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
NCT07572006Hematologic Neoplasms
Janssen Research & Development, LLC
Phase 1
360
Indiana, Michigan, New Jersey, New York, Tennessee, Texas
2026-05-13
Recruiting
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
NCT06930755Ovarian Cancer
DrugsNMS-03305293·Topotecan
Nerviano Medical Sciences
Phase 1
24
Illinois, Missouri, Pennsylvania, Tennessee, Texas
2026-05-13
Recruiting
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
NCT07501702Myasthenia Gravis, Generalized
DrugPovetacicept
Vertex Pharmaceuticals Incorporated
Phase 2
30
California, Florida, Hawaii, Illinois, Nevada, South Carolina, Tennessee, Texas
2026-05-13
Recruiting
CAPTURE-2: Controlled Arterial Protection to Ultimately Remove Embolic Material
NCT07276711Aortic Valve Stenosis, Aortic Stenosis, Aortic Valve Disease
EmStop Inc
Not applicable
663
California, Florida, Louisiana, Michigan, North Carolina, South Dakota, Texas
2026-05-12
Recruiting
Wearable Photoplethysmography for Non-invasive Hydration Assessment
NCT07520344Hydration Status
PepsiCo Global R&D
Not applicable
30
Texas
2026-05-12
Recruiting
Effect of the Amplifi™ Vein Dilation System on Outflow Vein Dilation and AV Fistula Maturation (AMPLIFI-1)
NCT07211035End Stage Kidney Disease (ESRD)
Amplifi Vascular, Inc.
Not applicable
160
Massachusetts, Texas
2026-05-12
Recruiting
A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
NCT07652047Obesity & Overweight
DrugCX11
Corxel Pharmaceuticals
Phase 1
90
Nevada, Texas
2026-05-11
Recruiting
Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers
NCT07539311Gastrointestinal Cancers
DrugRina-S
Genmab
Phase 2
160
Michigan, Texas
2026-05-11
Recruiting
A Study of TAK-505 in Adults With Solid Tumors
NCT07436728Malignant Solid Tumors
Takeda
Phase 1/2
151
California, Florida, Minnesota, New York, Ohio, Tennessee, Texas, Virginia
2026-05-11
Recruiting
A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
NCT07081997Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Ascendis Pharma Bone Diseases A/S
Phase 3
36
Colorado, Illinois, Minnesota, Nevada, New York, North Carolina, Texas, Washington
2026-05-07
Recruiting
Continuous Observational Monitoring Program for Allay™ Hydrogel Cap Safety and Success Study
NCT07246980Peripheral Nerve Injuries
Tulavi Therapeutics,Inc.
Observational
1,000
California, Colorado, Florida, Texas
2026-05-06
Recruiting
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
NCT07555483Alpha 1 Antitrypsin Deficiency
Grifols Therapeutics LLC
Phase 3
40
Alabama, Arizona, California, Florida, Minnesota, Ohio, South Carolina, Texas
2026-05-05
Recruiting
MyokinE100 System: Closed Loop Electrical Muscle Stimulation to Mitigate ICU Acquired Weakness in Medical ICU Patients
NCT07362862Sepsis, Critical Illness, ICU-acquired Muscle Weakness, ICU-acquired Weakness
Health Discovery Labs
Not applicable
50
Minnesota, Texas
2026-05-05
Recruiting
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
NCT07571005Obesity, Overweight, Obstructive Sleep Apnoea
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
300
California, Florida, Georgia, Illinois, New York, Ohio, Pennsylvania, Texas
2026-05-05
Not yet open
Occlutech AFR Fontan Study
NCT07532369Failure of Fontan Type Circulation, Fenestration, Univentricular Heart, Congenital Anomaly
Occlutech International AB
Observational
25
Alabama, California, Colorado, Illinois, North Carolina, Texas
2026-05-01
Recruiting
A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems
NCT07486102Healthy, Hepatic Impairment
DrugBI 3000202
Boehringer Ingelheim
Phase 1
44
Texas
2026-05-01
Recruiting
NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies
NCT07563829Metastatic Malignant Neoplasm
NextPoint Therapeutics, Inc.
Phase 1
81
California, Maryland, New York, Tennessee, Texas, Virginia
2026-05-01
Not yet open
The Safety and Efficacy of XytriX (Umbilical Cord-Derived Mesenchymal Stem Cells) in the Treatment of Knee Osteoarthritis
NCT07487766Osteoarthritis
TricelX Inc.
Phase 1/2
75
Texas
2026-05
Recruiting
18F-mFBG Cardiac Uptake With Lewy Body Dementia
NCT07176286Parkinson Disease (PD), Lewy Body Dementia (LBD)
Drug18F-MFBG
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Phase 2
20
Texas
2026-04-30
Recruiting
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
NCT07502508Type 2 Diabetes
DrugIcovamenib
Biomea Fusion Inc.
Phase 2
60
Alabama, California, Florida, Georgia, Nevada, Ohio, Texas, Virginia
2026-04-30
Recruiting
Observational Study of Adults and Adolescents With Erythropoietic Protoporphyria (EPP) and X-linked Porphyria (XLP)
NCT07567131Erythropoietic Protoporphyria (EPP), X-Linked Porphyria (XLP)
Portal Therapeutics, Inc.
Observational
50
Massachusetts, New York, North Carolina, Pennsylvania, Texas
2026-04-30
Recruiting
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
NCT07490301Metastatic Pancreatic Ductal Adenocarcinoma, PDAC
DrugsTelisotuzumab Adizutecan·Fluorouracil·Irinotecan·Oxaliplatin
AbbVie
Phase 2/3
900
Connecticut, Illinois, Michigan, Missouri, Ohio, Pennsylvania, Texas, Virginia
2026-04-30
Recruiting
Evaluating the Pharmacokinetics and Safety of Miricorilant
NCT07553663Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
Corcept Therapeutics
Phase 1
15
Texas
2026-04-30
Recruiting
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
NCT07469891Polycythemia Vera (PV), Myelofibrosis (MF), Myeloproliferative Neoplasms (MPNs), Post-Polycythemia Vera Myelofibrosis
Prelude Therapeutics Incorporated
Phase 1
100
California, Colorado, Florida, Michigan, Pennsylvania, Tennessee, Texas
2026-04-29
Recruiting
Descartes-08 in Autoantibody Myositis
NCT07391605Antisynthetase Syndrome
DrugDescartes-08
Cartesian Therapeutics
Phase 2
60
California, Massachusetts, North Carolina, Texas
2026-04-28
Recruiting
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
NCT07221669Muscular Atrophy, Spinal
DrugSalanersen
Biogen
Phase 3
30
Illinois, Texas, Virginia
2026-04-28
Recruiting
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
NCT07493512Metastatic Castration-resistant Prostate Cancer (mCRPC)
DrugXaluritamig
Amgen
Phase 1
40
Colorado, North Carolina, Ohio, Pennsylvania, South Dakota, Tennessee, Texas, Virginia
2026-04-28
Recruiting
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
NCT07516132Neovascular Age-Related Macular Degeneration (nAMD)
DrugOtx-Tki
Ocular Therapeutix, Inc.
Phase 3
850
California, Connecticut, Florida, Maryland, South Carolina, Texas
2026-04-27
Recruiting
A Phase 1 Study of Navlimetostat Tablet Formulations
NCT07544628Healthy Participants
DrugNavlimetostat
Bristol-Myers Squibb
Phase 1
64
Georgia, Texas
2026-04-27
Recruiting
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
NCT07232030Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III
CVRx, Inc.
Not applicable
2,500
Alabama, Florida, Missouri, Nebraska, Ohio, South Dakota, Tennessee, Texas
2026-04-24
Recruiting
Evaluation of Pain Treatment After Total Knee Arthroplasty
NCT07538570Pain
DrugSuzetrigine
Vertex Pharmaceuticals Incorporated
Phase 4
60
Texas
2026-04-24
Recruiting
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
NCT07565428Negative Symptoms of Schizophrenia
DrugsAripiprazole·Risperidone·Olanzapine
Minerva Neurosciences
Phase 3
380
California, Florida, Georgia, Maryland, New Jersey, New York, Texas
2026-04-23
Recruiting
Evaluation of Liver Stiffness Performance, by FibroScan®, to Detect Elevated Central Venous Pressure (CVP)
NCT07222813Heart Failure, Heart Failure - NYHA II - IV
Echosens
Not applicable
149
California, Minnesota, South Carolina, Texas
2026-04-23
Recruiting
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
NCT07271667Chronic Lymphocytic Leukemia, B-cell Malignancies
DrugsEmavusertib·Zanubrutinib
Curis, Inc.
Phase 2
108
Florida, Minnesota, New Jersey, Ohio, Pennsylvania, Texas
2026-04-23
Recruiting
Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants
NCT07250633Severe Hepatic Impairment, Normal Hepatic Function
DrugVorasidenib
Institut de Recherches Internationales Servier (I.R.I.S.)
Phase 1
20
Arizona, Florida, Texas
2026-04-23
Recruiting
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
NCT07596901Myasthenia Gravis, Generalized
Aurinia Pharmaceuticals Inc.
Phase 1/2
81
California, Florida, Illinois, Michigan, Texas
2026-04-22
Recruiting
A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors
NCT07612189Locally Advanced (Unresectable) or Metastatic Solid Tumors
NEOK Bio, Inc.
Phase 1
155
Florida, New York, Tennessee, Texas, Virginia
2026-04-22
Recruiting
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
NCT07558733HR+ HER2- Breast Cancer
DrugsSerabelisib·Sapanisertib·Fulvestrant
Faeth Therapeutics
Phase 1/2
32
California, Colorado, Oregon, Tennessee, Texas
2026-04-22
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
NCT07425522Diabetic Macular Edema
DrugFaricimab
Genentech, Inc.
Phase 1
93
Arizona, California, Florida, Maryland, Pennsylvania, Tennessee, Texas, Virginia
2026-04-21
Recruiting
A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants
NCT07635095Healthy Adult Participants
Astria Therapeutics, Inc.
Phase 1
180
Florida, Texas, Wisconsin
2026-04-21
Recruiting
A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
NCT07612176Locally Advanced (Unresectable) or Metastatic Solid Tumors
NEOK Bio, Inc.
Phase 1
155
New York, Tennessee, Texas, Virginia
2026-04-21
Recruiting
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
NCT07441876Achondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 2/3
160
California, Delaware, Illinois, Maryland, Ohio, Pennsylvania, Texas
2026-04-20
Recruiting
EVERO Drug-coated Balloon (DCB) Randomized Trial
NCT07144150Peripheral Vascular Disease, Peripheral Arterial Disease
Cook Research Incorporated
Not applicable
410
Connecticut, Florida, Iowa, Michigan, Mississippi, New Jersey, South Carolina, Texas
2026-04-17
Recruiting
Post Market Evaluation of Real World Outcomes and Durability to Support Implantable Inceptiv™ Spinal Cord Stimulation Therapy
NCT07507422Chronic Pain, Intractable Pain
Medtronic
Observational
970
Arizona, California, Missouri, Texas
2026-04-17
Recruiting
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
NCT06796504Relapsing Remitting Multiple Sclerosis
SetPoint Medical Corporation
Not applicable
60
California, Georgia, Maryland, Minnesota, Texas, Washington, West Virginia, Wisconsin
2026-04-17
Recruiting
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
NCT07241234Phenylketonuria
Agios Pharmaceuticals, Inc.
Phase 1
20
Indiana, Pennsylvania, Texas
2026-04-17
Recruiting
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT07545811Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer
Janux Therapeutics
Phase 1
43
California, Missouri, South Carolina, Tennessee, Texas
2026-04-15
Recruiting
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)
NCT07282847Pompe Disease (Late-onset), Pompe Disease Late-Onset, LOPD
AskBio Inc
Phase 1/2
12
Arizona, California, New York, North Carolina, Pennsylvania, Texas, Virginia
2026-04-15
Recruiting
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
NCT06451757Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS), Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
DrugSonlicromanol
Khondrion BV
Phase 3
220
Massachusetts, Ohio, Texas
2026-04-14
Recruiting
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
NCT07533006Alopecia Areata
DrugLY4005130
Eli Lilly and Company
Phase 2
60
California, Florida, Massachusetts, Michigan, New Hampshire, Texas, Utah
2026-04-14
Recruiting
Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass
NCT07015424Weight Regain, Weight Loss
Boston Scientific Corporation
Not applicable
108
California, Florida, Illinois, Maryland, Minnesota, New York, Texas, West Virginia
2026-04-14
Recruiting
A Study of GEN1106 in Participants With Solid Tumors
NCT07416123Solid Tumors, Urothelial Carcinoma
Genmab
Phase 1
103
Connecticut, New York, South Carolina, Tennessee, Texas
2026-04-14
Recruiting
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
NCT07414836Advanced Solid Tumor
DrugTislelizumab
BeOne Medicines
Phase 1
84
Massachusetts, Missouri, New Jersey, Texas
2026-04-13
Recruiting
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
NCT07517198Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Phase 1
40
California, Texas, Utah
2026-04-13
Recruiting
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07533175Diabetes Mellitus, Overweight, Obesity
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
630
Alabama, California, Florida, Minnesota, New York, South Carolina, Tennessee, Texas
2026-04-13
Recruiting
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
NCT07175441Advanced Unresectable Hepatocellular Carcinoma
DrugsSTRIDE (durvalumab·RBS2418·Tremelimumab
Riboscience, LLC.
Phase 2
220
Maryland, Tennessee, Texas
2026-04-10
Recruiting
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
NCT07524855Metastatic Breast Cancer
Janssen Research & Development, LLC
Phase 1
170
Connecticut, Florida, Massachusetts, Tennessee, Texas, Virginia
2026-04-09
Active, closed
Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity
NCT07523711Overweight, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 1
49
Texas, Wisconsin
2026-04-09
Recruiting
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
NCT07403721Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen
Phase 1
464
California, Illinois, Indiana, Maine, Tennessee, Texas
2026-04-08
Recruiting
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
NCT07297979Ewing Sarcoma
DrugXaluritamig
Amgen
Phase 1
50
California, Maryland, Massachusetts, Minnesota, New York, Pennsylvania, Texas
2026-04-08
Recruiting
A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation
NCT07535112Advanced/Metastatic Colorectal Adenocarcinoma
DrugCetuximab
Bayer
Phase 1
130
Arizona, California, Colorado, New York, Texas
2026-04-07
Recruiting
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
NCT07288112Refractory Melanoma
DrugDOC1021
Diakonos Oncology Corporation
Phase 1/2
35
Alabama, Arizona, California, Massachusetts, New Jersey, North Carolina, Texas
2026-04-06
Recruiting
Safety, PK and PD of FLQ-101 in Premature Neonates
NCT07093255Retinopathy of Prematurity (ROP)
FELIQS INC.
Phase 1
18
Texas
2026-04-03
Not yet open
Extensively Hydrolyzed Formula Growth Monitioring Study (GMS)
NCT07513506Growth
Mead Johnson Nutrition
Not applicable
214
Alabama, Arkansas, Florida, Illinois, Kentucky, North Carolina, Tennessee, Texas
2026-04-03
Recruiting
Confirmatory Clinical Study in Active Ulcerative Colitis
NCT07296315Colitis, Ulcerative
MRM Health NV
Phase 2
204
Florida, North Carolina, Texas
2026-04-03
Recruiting
A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillation
NCT07523750Atrial Fibrillation
Biosense Webster, Inc.
Not applicable
566
Arkansas, California, Florida, New York, North Carolina, Texas, Utah
2026-04-02
Recruiting
A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT07540221CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
DrugsGamunex-C·Xembify
Grifols Therapeutics LLC
Phase 3
40
California, Florida, New York, Tennessee, Texas
2026-04-02
Recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults
NCT07540910Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Enanta Pharmaceuticals, Inc
Phase 1
98
Texas
2026-04-01
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
NCT07355218Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
DrugEnpatoran
EMD Serono Research & Development Institute, Inc.
Phase 3
202
California, Florida, Indiana, Louisiana, Michigan, North Carolina, Texas
2026-04-01
Recruiting
A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients
NCT07472491Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion
DrugGadobutrol
GE Healthcare
Phase 2/3
640
Minnesota, Texas
2026-04-01
Recruiting
Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.
NCT06692712Hereditary Spastic Paraplegia Type 50
Elpida Therapeutics SPC
Phase 3
24
Texas
2026-04-01
Recruiting
Initial Safety of SFM Plus OTOLoc for Creating Side-to-side or End-to-side Colorectal Anastomoses
NCT07276529Colorectal Cancer, Diverticular Diseases
GI Windows, Inc.
Not applicable
30
Florida, Texas
2026-04-01
By invitation
A Study of Outcomes Following Bio-Reinforced Canaloplasty in Eyes With Open-Angle Glaucoma
NCT07520175Open-Angle Glaucoma
Iantrek, Inc.
Observational
300
California, Minnesota, Oregon, Pennsylvania, Texas
2026-04-01
Not yet open
Analysis of ECGio to Predict Coronary Stenosis Against a Mixed Reference Standard
NCT07375810Coronary Artery Disease (CAD)
Heart Input Output Inc
Observational
978
District of Columbia, Texas
2026-04-01
Recruiting
INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study
NCT07543367Neurological Disorder, ALS (Amyotrophic Lateral Sclerosis), Motor Neuron Disease, ALS - Amyotrophic Lateral Sclerosis
Synchron, Inc.
Not applicable
10
Florida, New York, Pennsylvania, Texas
2026-04
Not yet open
Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy
NCT07227285Urinary Bladder, Overactive, Spinal Cord Injury
DrugEG110A
Cyllene Therapeutics
Phase 1/2
16
California, Michigan, Pennsylvania, Texas
2026-04
Recruiting
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
NCT05936580Hemophilia A
DrugNuwiq
Octapharma
Phase 4
28
Texas
2026-04
Recruiting
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
NCT07552077Angiokeratomas
DrugPTX-022
Palvella Therapeutics, Inc.
Phase 2
15
California, Georgia, Nevada, Texas
2026-04
Recruiting
Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung
NCT07499674Lung Cancer, Lung Metastases
Vergent Bioscience, Inc.
Phase 3
132
California, Colorado, Florida, Michigan, Minnesota, Pennsylvania, Texas
2026-03-31
Recruiting
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
NCT07454642Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma
Avacta Life Sciences Ltd
Phase 1
174
Arizona, Florida, Illinois, Michigan, New York, Texas, Virginia
2026-03-31
Recruiting
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
NCT07439653Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TORL Biotherapeutics, LLC
Phase 1/2
155
California, Florida, Iowa, Kansas, Tennessee, Texas
2026-03-31
By invitation
Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections
NCT07456826Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion, Diabetic Retinopathy (DR)
DrugLidocaine Hydrochloride
Harrow Inc
Phase 4
236
Texas
2026-03-31
Recruiting
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
NCT07462377Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small Cell
EpiBiologics
Phase 1
110
California, New Jersey, New York, Tennessee, Texas
2026-03-31
Recruiting
Combined OFM and Vacuum-assisted Therapy for Expedited Regeneration Over Structures
NCT07385313Soft Tissue Defects, Soft Tissue Wounds, Traumatic Soft Tissue Defect
Aroa Biosurgery Limited
Phase 4
30
Colorado, Texas
2026-03-31
Recruiting
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
NCT07407933Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
DrugsTam-Peli·Atezolizumab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
118
District of Columbia, Florida, Kentucky, Texas, Virginia
2026-03-31
By invitation
Open-Label Extension Study to Pioneer Study 6058-SCD-101
NCT07401823Sickle Cell Disease
Fulcrum Therapeutics
Phase 2
50
Arkansas, California, Louisiana, Massachusetts, New York, Texas, Virginia
2026-03-30
Recruiting
Acute Pulmonary Embolism Treatment With the AlphaVac Multipurpose Mechanical Aspiration System and the AlphaReturn Blood Management System: Evaluation of Safety and Effectiveness
NCT07280247Pulmonary Embolism Acute
Angiodynamics, Inc.
Not applicable
39
Minnesota, New York, Ohio, Texas
2026-03-30
Recruiting
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
NCT07571746Primary Membranous Nephropathy
DrugSurovatamig
AstraZeneca
Phase 2
43
California, Iowa, Maryland, New York, Texas
2026-03-28
Recruiting
A 2-part Phase 1/2 Open-label Trial on ODM-212
NCT07563738Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
DrugsODM-212·Gemcitabine and nab-paclitaxel·Ipilimumab and nivolumab·Sotorasib
Orion Corporation, Orion Pharma
Phase 1/2
229
Texas, Virginia
2026-03-27
Recruiting
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
NCT07446439Nausea and Vomiting, Obesity
DrugTradipitant
Vanda Pharmaceuticals
Phase 3
280
California, Florida, New Jersey, New York, Texas, Virginia
2026-03-27
By invitation
A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma
NCT07338968Choroidal Melanoma, Indeterminate Lesions
Aura Biosciences
Observational
100
California, Michigan, Minnesota, Oklahoma, South Carolina, Tennessee, Texas, Utah
2026-03-27
Active, closed
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets
NCT07502495Type 2 Diabetes
DrugIcovamenib
Biomea Fusion Inc.
Phase 2
64
Alabama, California, Florida, Georgia, Nevada, Ohio, Texas, Virginia
2026-03-27
Active, closed
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
NCT07446998Obesity & Overweight, Mobility Disability, HOMA-IR
DrugSemaglutide (Wegovy)
Veru Inc.
Phase 2
239
Arizona, Florida, Louisiana, Maryland, Mississippi, New York, North Carolina, Texas
2026-03-26
Recruiting
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
NCT07493265Narcolepsy
DrugE2086
Eisai Inc.
Phase 2
64
California, Florida, Georgia, Maryland, Michigan, North Carolina, South Carolina, Texas
2026-03-26
Recruiting
Image Evaluation of Intalight Dream OCTA Scans With Optos FA & ICGA Images
NCT07568704Retina Pathology
Intalight, Inc
Observational
30
Texas
2026-03-25
Recruiting
A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.
NCT07445971COVID -19, COVID-19 (Prevention)
ModeX Therapeutics, An OPKO Health Company
Phase 1
80
Nevada, Texas
2026-03-24
Recruiting
A Study of Mirikizumab Solution (LY3074828) in Healthy Participants
NCT07446101Healthy
DrugMirikizumab
Eli Lilly and Company
Phase 1
450
Florida, Minnesota, Texas, Wisconsin
2026-03-24
Recruiting
Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes
NCT07216235Primary Biliary Cholangitis
DrugSaroglitazar Magnesium
Zydus Therapeutics Inc.
Phase 3
386
Georgia, Indiana, Texas
2026-03-24
Recruiting
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
NCT07293260Cardiovascular Disease
DrugOlpasiran
Amgen
Phase 3
406
Connecticut, Florida, Kansas, Maryland, Pennsylvania, Texas
2026-03-23
Recruiting
Post Market Clinical Study to Evaluate the Performance of the Versius Surgical System
NCT07096856Cholecystectomy, Robotic
CMR Surgical Ltd
Not applicable
100
California, Texas
2026-03-23
Recruiting
First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors
NCT07438782Neoplasms
GlaxoSmithKline
Phase 1
97
Pennsylvania, Texas
2026-03-23
Recruiting
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
NCT07405164Von Hippel-Lindau Disease, Malignant Neoplasms
DrugsBelzutifan·Cabozantinib·Lenvatinib·Nivolumab
Merck Sharp & Dohme LLC
Phase 3
450
Massachusetts, Michigan, Pennsylvania, Tennessee, Texas, Washington
2026-03-23
Recruiting
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
NCT07546760Hepatic Impairment
DrugsAZD9550·Lenbelintide
AstraZeneca
Phase 1
28
Arizona, California, Florida, Texas
2026-03-20
Recruiting
Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis
NCT07293871Rheumatoid Arthritis
Surf Therapeutics
Not applicable
40
Texas
2026-03-20
By invitation
Evaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate (MF)
NCT07286201Chronic Rhinosinusitis (CRS), Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Polyganics BV
Not applicable
110
Colorado, Georgia, Illinois, Louisiana, Maryland, South Carolina, Texas, Utah
2026-03-19
Recruiting
Study in Advanced Solid Tumor Patients
NCT07300943Advanced Solid Tumor
Callio Therapeutics
Phase 1/2
306
Massachusetts, Tennessee, Texas, Utah
2026-03-19
Recruiting
Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
NCT07538583Netherton Syndrome
Quoin Pharmaceuticals
Phase 2/3
16
California, Connecticut, Indiana, Massachusetts, Texas
2026-03-19
Active, closed
A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity
NCT07476118Obesity, Overweight
DrugBrenipatide
Eli Lilly and Company
Phase 1
150
Florida, Texas, Wisconsin
2026-03-18
Recruiting
First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors
NCT07362888Solid Tumors (Phase 1)
Adcendo ApS
Phase 1
180
Arkansas, Connecticut, Texas
2026-03-17
Recruiting
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
NCT07540572ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma
DrugFulvestrant
IDEAYA Biosciences
Phase 1
160
Florida, New Jersey, New York, Texas, Utah, Virginia
2026-03-17
Recruiting
Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
NCT07446855Solid Tumours
DrugSaruparib
AstraZeneca
Phase 1/2
180
New York, Rhode Island, Texas, Virginia
2026-03-17
Recruiting
Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis
NCT07285070Non-infectious Anterior Uveitis
Novaliq GmbH
Phase 2
20
Arizona, Florida, Massachusetts, New Jersey, Texas, Virginia
2026-03-16
Active, closed
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
NCT07431086Overweight or Obesity
DrugOlatorepatide
Regeneron Pharmaceuticals
Phase 2
120
California, Florida, Texas
2026-03-16
Not yet open
A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies
NCT06906380Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapsed or Refractory, MDS (Myelodysplastic Syndrome)
ARCE Therapeutics, Inc.
Observational
49
North Carolina, Texas
2026-03-15
Recruiting
Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy
NCT07220785Generalized Lipodystrophy
DrugMibavademab
Regeneron Pharmaceuticals
Phase 3
28
Michigan, Texas
2026-03-13
Recruiting
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
NCT07358546Non-alcoholic Fatty Liver Disease
DrugEfimosfermin alfa
GlaxoSmithKline
Phase 1
32
California, Florida, Texas
2026-03-13
By invitation
Post-market SUrveiLlance RegiStry for the Endogenex System (Endogenex PULSE Registry)
NCT07197775Type 2 Diabetes Mellitus (T2DM), Type2Diabetes, Diabetes Mellitus, Type 2, Type 2 Diabetes
Endogenex, Inc.
Observational
500
Massachusetts, North Carolina, Texas
2026-03-11
Active, closed
Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support (VR-CARES)
NCT07430371Direct Care Workers, Dementia Caregiver, In-Home Care, Caregiver Social Support
Rendever, Inc.
Not applicable
30
California, Massachusetts, Michigan, Texas
2026-03-11
Recruiting
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
1,182
Arizona, California, Colorado, Florida, Maryland, Ohio, Tennessee, Texas
2026-03-11
Recruiting
A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea
NCT07235917Functional Hypothalamic Amenorrhea, FHA
DrugMibavademab
Regeneron Pharmaceuticals
Phase 2
34
Arizona, California, Connecticut, Florida, Oregon, Pennsylvania, Texas, Virginia
2026-03-11
Recruiting
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
NCT07457918Common Warts (Verruca Vulgaris), Common Warts, Human Papilloma Virus (HPV), Warts
Verrica Pharmaceuticals Inc.
Phase 3
600
Florida, Indiana, Ohio, Texas
2026-03-11
Active, closed
Endometrial Cancer Vaginal Fluid Specimen Collection Study
NCT07544680Abnormal Uterine Bleeding (AUB), Endometrial Cancer, Atypical Endometrial Hyperplasia, Endometrial Hyperplasia With Atypia
Exact Sciences Corporation
Observational
4,200
Florida, Maine, Tennessee, Texas
2026-03-10
Recruiting
A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)
NCT07408232Retinitis Pigmentosa
Octant, Inc.
Phase 1/2
18
Oregon, Texas
2026-03-10
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
DrugEnpatoran
EMD Serono Research & Development Institute, Inc.
Phase 3
202
California, Florida, Georgia, Michigan, Texas
2026-03-10
Recruiting
A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
NCT07464314Influenza, Human+COVID-19
GlaxoSmithKline
Phase 1
225
Alabama, Arkansas, California, Florida, Georgia, Texas, Virginia, Washington
2026-03-09
Recruiting
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07441642Geographic Atrophy Secondary to Age-related Macular Degeneration
Novartis Pharmaceuticals
Phase 2
272
California, Florida, Massachusetts, New Jersey, New York, Pennsylvania, Texas
2026-03-09
Recruiting
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
NCT07410117Cancer-Associated Thrombosis (CAT)
DrugCenvacibart
Regeneron Pharmaceuticals
Phase 3
1,120
Florida, New York, Texas
2026-03-09
Recruiting
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT07218341Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
DrugsIdelalisib·Pirtobrutinib
Eli Lilly and Company
Phase 4
150
Alabama, Arizona, Florida, Minnesota, New York, Ohio, Texas
2026-03-09
Active, closed
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
NCT07441252Overweight or Obesity and Elevated Liver Fat
DrugMaridebart cafraglutide
Amgen
Phase 2
180
Arizona, California, Florida, Louisiana, Maryland, Missouri, Nevada, Texas
2026-03-05
Recruiting
TOUCH® CMC 1 New Enrollment US Study
NCT07405983Osteoarthritis Thumb, Thumb Carpometacarpal Joint Osteoarthritis
Keri Medical SA
Observational
163
Colorado, Indiana, North Carolina, Texas
2026-03-04
Recruiting
Radiprodil in Participants With Hepatic Impairment
NCT07457229Hepatic Impairment
DrugRadiprodil
GRIN Therapeutics, Inc.
Phase 1
40
Texas
2026-03-03
By invitation
Long-Term Follow Up of VOY-101 Non-nAMD Extension Study
NCT07660640Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
DrugVOY-101
Perceive Biotherapeutics, Inc.
Observational
88
Massachusetts, Texas, Utah
2026-03-03
Recruiting
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
NCT07424547Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate
DrugSYS6043
Conjupro Biotherapeutics, Inc.
Phase 1
386
Florida, Texas, Virginia
2026-03-03
By invitation
Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy
NCT07503613Vestibular Schwannoma
Akouos, Inc.
Observational
100
Texas
2026-03-02
Recruiting
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
NCT07615426Schizophrenia
Janssen Research & Development, LLC
Phase 1
64
California, Georgia, Illinois, Michigan, New York, Texas
2026-03-02
Recruiting
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
NCT07453602Atopic Dermatitis (AD), Eczema
Arcutis Biotherapeutics, Inc.
Phase 1
125
Florida, Indiana, New Jersey, Texas, Utah
2026-03-02
Not yet open
Validate the Temporal Stability and Responsiveness of AI-COA® for Depression and Anxiety
NCT07279025Depression Disorders, Anxiety Disorders
Deliberate Solutions Inc.
Observational
150
Texas
2026-03-01
Not yet open
Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest
NCT03176186Post-Cardiac Arrest Syndrome
Invero Pharma, Inc.
Phase 3
1,436
Connecticut, Florida, Mississippi, Nebraska, New York, Ohio, Tennessee, Texas
2026-03
Active, closed
A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
NCT07427797Moderate to Severe Glabellar Lines
DrugCorabotase
Ipsen
Phase 3
309
Alabama, Arizona, California, Florida, Maryland, South Carolina, Texas, Virginia
2026-02-27
Recruiting
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
NCT07306559Advanced Relapsed or Refractory Germ Cell Tumours, Advanced Relapsed or Refractory Endometrial Cancer, Advanced Relapsed or Refractory Ovarian Cancer
Boehringer Ingelheim
Phase 1
187
California, Indiana, Texas
2026-02-27
Recruiting
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
NCT07168993Lung Cancer (Diagnosis)
bioAffinity Technologies Inc.
Not applicable
2,063
California, Colorado, Florida, Illinois, Ohio, Pennsylvania, Texas, Wisconsin
2026-02-25
Recruiting
A Study of BI 3810944 in Patients With Advanced Cancer
NCT07224425Solid Tumours, Melanoma
Boehringer Ingelheim
Phase 1
69
Kentucky, Tennessee, Texas, Virginia
2026-02-24
Recruiting
Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System
NCT07335341Venous Embolism of Lower Extremities (Diagnosis), Arterial Embolism and Thrombosis, Acute DVT of Lower Extremity, Chronic DVT of Lower Extremity
Medtronic Endovascular
Observational
50
District of Columbia, Florida, New York, Texas
2026-02-24
Recruiting
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT07503808Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
IDEAYA Biosciences
Phase 1
150
Colorado, Florida, Michigan, New York, Tennessee, Texas, Utah, Virginia
2026-02-24
Recruiting
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
NCT07189871Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer
Radiopharm Theranostics, Ltd
Phase 1/2
61
Alabama, Michigan, Nebraska, Texas
2026-02-23
Recruiting
Study of DISC-0974-201 in Participants With IBD and Anemia
NCT07368972Inflammatory Bowel Disease (IBD), Anemia, Inflammatory Bowel Disease (IBD); Anemia
DrugDISC-0974
Disc Medicine, Inc
Phase 2
21
Alabama, Arizona, California, Florida, Missouri, Ohio, Rhode Island, Texas
2026-02-20
Recruiting
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
NCT07047690Systemic Sclerosis
DrugNemolizumab
Galderma R&D
Phase 2
162
Michigan, Texas
2026-02-20
Recruiting
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
NCT07432633Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer, Invasive Lobular Breast Carcinoma
Blue Earth Diagnostics
Phase 1/2
71
Texas
2026-02-19
Recruiting
A Clinical Trial Comparing 2x/Day for 30-minutes Use of the Emanate Perio PODS Post-SRP to a Control Group Post-SRP.
NCT06914596Periodontitis (Stage 3)
McGuire Institute
Not applicable
72
California, Connecticut, Massachusetts, Nebraska, Texas, Virginia, Washington
2026-02-19
Recruiting
Ambulatory Long Length URodynamics Evaluation
NCT07425015Urology, Urinary Bladder, Overactive, Benign Prostatic Hyperplasia, Urodynamics
Bright Uro
Not applicable
101
Louisiana, Maryland, Missouri, Ohio, South Carolina, South Dakota, Texas, Washington
2026-02-17
Recruiting
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
NCT07362017Moderate-to-severe Chronic Plaque Psoriasis
DrugPonesimod
Vanda Pharmaceuticals
Phase 3
300
Arizona, California, Florida, Indiana, New Hampshire, New York, North Carolina, Texas
2026-02-17
Recruiting
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
NCT07465835T Cell Malignancies
DrugELA026
Electra Therapeutics Inc.
Phase 1
84
Connecticut, Georgia, Michigan, New York, Ohio, Texas
2026-02-17
Recruiting
Effect of Sage Extract Supplementation on Cognitive Function in Middle-Aged Men and Women
NCT07757529Cognitive Ability, General
ESM Technologies, LLC
Not applicable
64
Texas
2026-02-15
By invitation
Validation and Usability Study of the SleepView+ Home Sleep Testing System for the Evaluation of Moderate to Severe Obstructive Sleep Apnea.
NCT07476313Obstructive Sleep Apnea
Beacon Biosignals
Observational
200
California, New York, Ohio, Texas
2026-02-15
Recruiting
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
NCT07337525Advanced Malignant Solid Tumor, Solid Tumor Cancer
Pilatus Biosciences Inc
Phase 1
36
California, Texas
2026-02-13
Recruiting
Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
NCT07107126Acute Myeloid Leukemia, Myelodysplastic Syndrome
Remedy Plan, Inc.
Phase 1
24
New York, Texas
2026-02-13
Recruiting
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
NCT07360314Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.
Phase 1
138
Connecticut, North Carolina, Texas
2026-02-13
Recruiting
A Study of Patients With Fabry Disease (US Specific)
NCT06906367Fabry Disease
DrugMigalastat HCl
Amicus Therapeutics
Observational
450
Alabama, Arkansas, Georgia, Missouri, New York, Pennsylvania, Texas, Virginia
2026-02-13
Recruiting
Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy
NCT07215273Invasive Mould Infection
DrugVoriconazole
Elion Therapeutics, Inc.
Phase 2
60
Alabama, California, Georgia, Maryland, Massachusetts, Michigan, Missouri, Texas
2026-02-13
Recruiting
Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients
NCT07211659Ovarian Cancer
DrugTHEO-260
Theolytics Limited
Phase 1
18
Texas
2026-02-13
Recruiting
ROME GS System Study
NCT07518004Diabetes, Diabetes Melletus, Type 1, Diabetes Mellitus, Type 2
Senseonics, Inc.
Not applicable
60
California, Texas, Washington
2026-02-12
Recruiting
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
NCT07285785Diarrhea, Gastroenteritis, Bacterial Infection, Acute Diarrhea
DrugRifaximin
Bausch Health Americas, Inc.
Phase 4
54
California, Florida, Georgia, Illinois, Oregon, Texas, Virginia
2026-02-11
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.
NCT07401862Hepatic Insufficiency
DrugEloralintide
Eli Lilly and Company
Phase 1
36
Florida, Texas
2026-02-10
Recruiting
Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery
NCT07206121Breast Cancer, Breast-conserving Surgery, Breast Cancer - Infiltrating Ductal Carcinoma, ER/PR+Her2neu
Innoblative Designs, Inc.
Not applicable
10
Texas
2026-02-10
Recruiting
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
NCT07201129Nephritis, Lupus, Lupus Erythematosus, Systemic
DrugCenerimod
Viatris Innovation GmbH
Phase 3
300
Florida, Michigan, Texas
2026-02-09
Recruiting
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
NCT07213830Advanced Solid Tumor, Metastatic Solid Tumor
Ipsen
Phase 1/2
102
Michigan, Tennessee, Texas
2026-02-06
Recruiting
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
NCT07365462Tardive Dyskinesia
Neurocrine Biosciences
Phase 2
100
Arkansas, California, Florida, Georgia, Nebraska, Ohio, Texas
2026-02-06
Recruiting
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
NCT07250750Myasthenia Gravis
ImmunAbs Inc.
Phase 1/2
96
Florida, Missouri, Texas
2026-02-05
Recruiting
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
NCT07222332Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
300
Colorado, Florida, Pennsylvania, Texas, Virginia
2026-02-05
Recruiting
A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
NCT07372625TP53 Y220C Mutation, Advanced Solid Tumors
DrugsRezatapopt·Repaglinide·Midazolam Hydrochloride·Metformin Hydrochloride
PMV Pharmaceuticals, Inc
Phase 1
14
Colorado, Florida, Tennessee, Texas
2026-02-04
Recruiting
Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking
NCT07102160Deep Vein Thrombosis (DVT), Thrombus in the Peripheral Venous Vasculature, Venous Embolism, Thrombus in the Central and Peripheral Circulatory System, Including Saphenous Vein Grafts
Argon Medical Devices
Observational
185
Florida, Kentucky, Texas
2026-02-04
Recruiting
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
NCT07224321Type 1 Diabetes Mellitus
Mannkind Corporation
Phase 2
100
California, Colorado, Connecticut, Florida, Indiana, Massachusetts, Oklahoma, Texas
2026-02-04
Active, closed
Evaluate RLS-1496 Topical Cream for Actinic Keratosis
NCT07340697Actinic Keratosis (AK)
Rubedo Life Sciences, Inc.
Phase 1/2
24
Arkansas, Minnesota, Nebraska, Texas
2026-02-03
Recruiting
Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury
NCT06654193Acute Kidney Injury
Hope Biosciences LLC
Phase 1/2
70
Alabama, California, Texas
2026-02-01
Recruiting
Effects of Eggshell Membrane and Curcumin Extract Supplementation, Separately or Combined, on Recovery From Intense Exercise
NCT07766720Exercise-induced Muscle Soreness, Exercise-induced Joint Pain, Exercise-induced Joint Stiffness, Exercise-induced Cartilage Turnover
ESM Technologies, LLC
Not applicable
60
Texas
2026-02-01
Recruiting
A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses
NCT07330674Age Related Macular Degeneration (ARMD), AMD - Age-Related Macular Degeneration
Aptabio Therapeutics, Inc.
Phase 1
68
Texas
2026-02
Not yet open
Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men
NCT07328542Hypogonadism, Male
DrugTestosterone Cypionate
Azurity Pharmaceuticals
Phase 4
144
Alabama, Florida, New York, Texas, Utah
2026-02
Recruiting
Flourish: Exploring the Early Infant Gut Microbiome
NCT07333482Microbiota, Gut Microbiome, Eczema, Microbiome
Seeding Inc
Not applicable
250
Texas
2026-01-31
Recruiting
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC
DrugsElironrasib·Zoldonrasib·Ivonescimab·Cetuximab
Revolution Medicines, Inc.
Phase 1/2
370
California, Connecticut, Minnesota, Tennessee, Texas, Virginia
2026-01-30
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
DrugsSigvotatug vedotin·PF-08634404
Pfizer
Phase 1/2
162
Arkansas, California, Colorado, Florida, New Jersey, New York, Oregon, Texas
2026-01-30
Recruiting
A Prospective Multicenter Clinical Investigation Evaluating the Accuracy of the Trimline Design When Treated With SureSmile® Aligners.
NCT07290790Malocclusion
Dentsply Sirona Implants and Consumables
Not applicable
90
California, New Jersey, North Carolina, Texas
2026-01-29
Recruiting
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
NCT06875128Metastatic Breast Cancer in the Liver
DrugCapecitabine
Delcath Systems Inc.
Phase 2
90
Florida, Ohio, Texas
2026-01-29
Active, closed
A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
NCT07363720Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
DrugTAK-861
Takeda
Phase 3
98
California, Florida, Michigan, New Jersey, North Carolina, Ohio, South Carolina, Texas
2026-01-29
Active, closed
Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures
NCT07505004Focal Epilepsy
Praxis Precision Medicines
Phase 3
300
Florida, New Jersey, New York, North Carolina, Texas
2026-01-29
Recruiting
Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease
NCT07439887Stargardt Disease
Ray Therapeutics, Inc.
Phase 1/2
18
California, Pennsylvania, Texas
2026-01-28
Recruiting
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
NCT07252479Solid Tumors (Phase 1), RAS Mutation
Adlai Nortye Biopharma Co., Ltd.
Phase 1
118
Florida, Texas
2026-01-28
Recruiting
tAN for Substance Use Disorder
NCT07281261Alcohol Use Disorder, Alcohol Abuse, Substance Use Disorders, Substance Use Disorders Alcohol Use Withdrawal State
Spark Biomedical, Inc.
Not applicable
20
Texas
2026-01-28
Recruiting
Evaluation of the Rigicon Infla10® Inflatable Penile Prosthesis (IPP) for Erectile Dysfunction
NCT07273773Erectile Dysfunction (ED)
Rigicon, Inc.
Not applicable
182
Florida, Georgia, Texas
2026-01-26
Active, closed
RPMO2 Oximeter Accuracy During Sleep 1 Trial
NCT07397780Obstructive Sleep Apnea
ProSomnus Sleep Technologies
Observational
30
Texas
2026-01-22
Recruiting
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
NCT07247188Sickle Cell Disease
DrugsCapvaxive·Prevnar 20
Sanofi
Phase 3
100
Georgia, Nebraska, New Jersey, Texas
2026-01-20
Recruiting
A Study to Evaluate the Effect of KarXT on Urological Safety
NCT07221877Schizophrenia
DrugKarXT
Bristol-Myers Squibb
Phase 4
60
Arkansas, California, Florida, Illinois, Nevada, New Jersey, Pennsylvania, Texas
2026-01-20
Recruiting
Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age
NCT07348692Pneumococcal Immunization, Healthy Volunteers
DrugsPCV21 vaccine·Prevnar 20
Sanofi
Phase 3
2,195
Arkansas, California, Florida, Kentucky, Michigan, New York, South Carolina, Texas
2026-01-20
Recruiting
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
NCT07262619Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer
DrugsKeytruda·Pembrolizumab
Eikon Therapeutics
Phase 1/2
160
California, Florida, New Jersey, New York, Texas
2026-01-20
Recruiting
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
NCT07230834Geographic Atrophy (GA)
DrugPozelimab
Regeneron Pharmaceuticals
Phase 1
54
Colorado, Massachusetts, Texas
2026-01-19
Recruiting
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
NCT07276373Neoplasms
DrugNivolumab
Corcept Therapeutics
Phase 1/2
50
California, Illinois, Michigan, Texas, Utah
2026-01-16
Recruiting
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
NCT07053800Lupus Nephritis
DrugObecabtagene autoleucel
Autolus Limited
Phase 2
35
New York, Texas
2026-01-16
Recruiting
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
NCT07235293Colorectal Cancer
DrugsDSP107·Fruquintinib·Atezolizumab
Kahr Bio Australia Pty Ltd
Phase 2
90
Colorado, Florida, North Carolina, Pennsylvania, Texas
2026-01-16
Recruiting
Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study
NCT07114718Congenital Heart Disease, Congenital Heart Disease (CHD)
Starlight Cardiovascular Inc
Not applicable
45
California, Colorado, Massachusetts, Ohio, Pennsylvania, Texas, Washington
2026-01-16
Recruiting
A Study of LY4515100 in Healthy Participants
NCT07339722Healthy
DrugsLY4515100·Iohexol·Digoxin·Caffeine
Eli Lilly and Company
Phase 1
123
Texas
2026-01-15
Recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
NCT07321106Colorectal Cancer, Colorectal Cancer (CRC), Colorectal (Colon or Rectal) Cancer, CRC
Cartography Biosciences
Phase 1
80
Arizona, California, Florida, Georgia, Michigan, Texas, Virginia
2026-01-15
Recruiting
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
NCT07195682Renal Cell Carcinoma
DrugsPumitamig·Yervoy·Ipilimumab
Bristol-Myers Squibb
Phase 1
281
Massachusetts, New York, Pennsylvania, Tennessee, Texas
2026-01-15
Active, closed
A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
NCT07298330Chronic Hepatitis D Infection
DrugBulevirtide
Mirum Pharmaceuticals, Inc.
Phase 3
80
California, Colorado, Nevada, Ohio, Texas, Utah
2026-01-14
Recruiting
A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment
NCT07006688IDH1-Mutated Malignancies
DrugIvosidenib
Servier Bio-Innovation LLC
Phase 1
30
Georgia, Ohio, Texas
2026-01-14
Recruiting
The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment
NCT07643896Pregnant Individuals, Aneuploidy, Down Syndrome (Trisomy 21), 22q11.2 Deletion Syndrome
BillionToOne Inc.
Observational
1,000
Arizona, California, Florida, Georgia, Louisiana, Texas
2026-01-10
Recruiting
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
NCT07155226Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes
DrugPosaconazole
AstraZeneca
Phase 1/2
84
Illinois, New York, North Carolina, Oregon, Texas
2026-01-09
Recruiting
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
NCT07195916Solid Tumors, Hematologic Malignancies
Incyte Corporation
Phase 1
280
California, Michigan, Nebraska, New York, Tennessee, Texas
2026-01-08
Active, closed
Nicotine Pouch Pharmacokinetics Abuse Liability
NCT07476144Smoking Behaviors
JT International SA
Phase 1
55
Tennessee, Texas
2026-01-08
Recruiting
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT07349537Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 1
574
Connecticut, Maryland, Massachusetts, Michigan, New York, Texas, Virginia
2026-01-08
Recruiting
An External Control Arm Study in Non-Small Cell Lung Cancer
NCT07174388Non Small Cell Lung Cancer
N-Power Medicine
Observational
650
California, Delaware, Illinois, New Mexico, New York, Pennsylvania, Texas
2026-01-07
Rows per page Showing 1–500 of 1965
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/texas

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,965 of those studies with a site in Texas.

How many clinical trials are recruiting in Texas?

1,184 of the 1,965 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 101 have not yet opened recruitment, 623 are active but closed to new participants, and 57 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Texas), 1,965 studies
PhaseStudiesRecruitingShare
Phase 155337028.1%
Phase 1/233923417.3%
Phase 231716816.1%
Phase 324913312.7%
Not applicable23312711.9%
Observational20711310.5%
Phase 432221.6%
Phase 2/330141.5%
Phase EARLY_PHASE1530.3%

Most active sponsors

Lead sponsors with the most studies (Texas)
Lead sponsorStudiesRecruiting
AstraZeneca5325
Novartis Pharmaceuticals4424
Eli Lilly and Company3318
GlaxoSmithKline3119
Merck Sharp & Dohme LLC3121
AbbVie3020
Amgen2410
Hoffmann-La Roche236
Regeneron Pharmaceuticals2317
Sanofi2210
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.